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Abstract  
Squamous cell carcinoma of mucosal head and neck sites (HNSCC) is the sixth most common cause 
of cancer world-wide, and is associated with a significant morbidity and mortality despite advances 
in therapeutic options over the past decades. HNSCC includes tumours of the oral cavity, oropharynx, 
larynx and hypopharynx. While there has been a decline in tumours occurring as a result of exposure 
to the traditional risk factors of tobacco smoking and alcohol consumption, a significant increase has 
been observed in the number of tumours attributed to the Human Papillomavirus (HPV). This has 
primarily been associated with causation of tumours in the oropharynx, however, a smaller number 
of tumours at other subsites are also likely to be related to the virus. Although HPV-related tumours 
tend to have an improved prognosis and a better response to chemo- and radiotherapy, the 
pathobiology underlying these differences is not yet fully understood. 
 
MiRNAs are short, non-coding single strands of RNA which regulate gene expression at the post-
transcriptional level. They have been identified to be dysregulated and function as tumour suppressor 
or oncogenes in a number of human cancers, including head and neck cancers. MiRNAs have also 
been associated with prognostication including associations with recurrence of disease and disease-
free survival. As they are readily available across a range of body tissues including solid tissue, saliva, 
and plasma, these biomarkers have potential utility in relation to screening for disease diagnosis, 
recurrence or progression. Although there is an established difference between HPV-positive and 
negative tumours in the oropharynx clinically, the majority of studies investigating miRNA 
expression in HNSCC have not taken this factor into account. In the small number of studies which 
have examined the effect of HPV on miRNA expression in HNSCC, there is a lack of consistency in 
the results described.  
 
This thesis aimed to assess the difference in miRNA expression between HPV-positive and negative 
tumours, through use of miRNA microarray followed by validation with real-time PCR using 
TaqMan assays combined with a sensitive detection method (Fluidigm HD) in a larger cohort of 
patients. It also investigated differences in miRNA expression in association with lifestyle factors, 
demographics and clinical outcomes. A set of seven miRNAs was identified to be differentially 
expressed between HPV-positive and negative tumours in the oropharynx. No difference in miRNA 
expression was observed between the two tumour cohorts at other subsites in the head and neck. 
Differences in miRNA expression were also observed with lifestyle factors such as smoking status 
and alcohol consumption. Recurrence of the primary tumour and overall disease-free survival were 
further associated with altered miRNA expression. The findings outlined in this thesis add to the 
present literature regarding differences in miRNA expression between HPV-positive and negative 
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tumours in the oropharynx, and provide a basis for further research to focus on the use of miRNAs 
for diagnosis or prognosis in HNSCC. 
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CHAPTER ONE: Introduction 
1.1 Mucosal Head and Neck Cancer  
1.1.1 Epidemiology 
Squamous cell carcinoma (SCC) of the head and neck cancer (HNSCC) is the sixth most common 
cause of cancer worldwide [1, 2]. In Australia, it affects approximately 4000 persons per year (3.4% 
of all cancer diagnoses per year in Australia), which has increased over the past two decades [3, 4]. 
This includes SCC of mucosal anatomic sub-sites: oral cavity (tongue, buccal mucosa), oropharynx 
(base of tongue, palatine tonsil), hypopharynx (posterior pharyngeal wall, post-cricoid region) and 
larynx (glottis, supraglottis, subglottis). Mortality rates remain high despite advances in conventional 
therapy, with an approximately 68% 5-year survival rate in Australia at present [3]. Further, 
significant morbidity is associated not only with diagnosis but also with treatments. This may range 
from physical disfigurement and low self-esteem to radiation induced swallowing difficulties and 
xerostomia, to difficulty with speech and overall reduced quality of life. The majority of HNSCCs 
continue to be diagnosed at a later stage, resulting in more extensive disease, and contributing to the 
overall low survival rate [4]. Traditionally, tobacco smoking and alcohol consumption are risk factors 
for this disease, having synergistic carcinogenic effects, and tumours related to these risk factors have 
demonstrated a stabilization or decline in incidence [1, 2, 5, 6]. Human papillomavirus (HPV) 
infection is also now an established risk factor for a subset of HNSCC, particularly HNSCC occurring 
in the oropharynx (base of tongue and palatine tonsils), following its discovery in these tumours in 
1983 by Syrjanen et al  [1, 7-9]. Since this time, there has been a clear and significant increase in the 
incidence of oropharyngeal tumours related to HPV of 225% between 1984 and 2004 in America, as 
well as a decrease of approximately 50% of HPV-negative tumours [10].  
 
1.1 .2 Staging 
A tissue diagnosis remains the gold standard for a diagnosis of HNSCC, and can include either a 
biopsy of the primary tumour site or a fine needle aspirate of a neck lymph node. Clinical examination 
of the head and neck, in combination with imaging techniques such as computed tomography (CT), 
magnetic resonance imaging (MRI) and positive emission tomography (PET) with fluoro-2-
deoxyglucose (FDG) are used to accurately stage patients. Mucosal HNSCC is staged according to 
the 7th American Joint Committee on Cancer (AJCC) TNM classification [11]. The T stage is used to 
refer to the extent of the primary tumour, while the N stage indicates whether there is any involvement 
of loco-regional lymph nodes. The M stage refers to the presence or absence of distant metastatic 
disease. Accurate staging of patients at diagnosis allows for suitable treatment regimens to be 
instituted by a multidisciplinary team and permits appropriate prognostication.   
2 | 97 
 
1.2 Human papillomavirus associated head and neck cancer  
HPV has been well studied in the context of cervical carcinoma in women, but the role of HPV as an 
etiologic agent in HNSCC was first postulated in 1983 by Syrjanen et al [9, 12]. Since this time, the 
oncogenic role of HPV-16 in oropharyngeal SCC has been established by the International Agency 
for Research on Cancer [7]. In oropharyngeal SCCs, HPV has an estimated prevalence of 50%-60%, 
but HPV DNA has been detected in up to 90% of oropharyngeal tumors [2, 5]. When the presence of 
HPV-DNA is combined with p16INK4a positivity or E6/E7 mRNA, the attributable fraction of HPV in 
the oropharynx is approximately 40% according to a meta-analysis in 2014; however, at present 
clinically, up to 70% of patients presenting with oropharyngeal SCCs have HPV-associated tumours 
[2].  
 
1.2.1 Clinical and Pathologic features  
Patients with HPV-positive disease in the oropharynx clinically have distinctly different disease to 
HPV-negative tumors. These tumors tend to occur in younger (40-55 years, compared with >60 
years), male, Caucasian patients, as well as be associated with higher levels of education achieved, 
higher income and higher socio-economic status [5, 8, 13, 14]. The patients tend to have lower levels 
of tobacco and alcohol consumption  [1, 8]. The tumors are more likely to be of non-keratinizing or 
basaloid morphology histologically, and while they present at an earlier T-stage, there is an 
association with advanced nodal disease at diagnosis [5, 14]. An improved responsiveness to 
chemotherapy and radiotherapy has been reported, as well as an overall improved survival rate [5, 
13, 14].  
 
1.2.2 Role of HPV in non-oropharyngeal tumours 
While high-risk HPV has been isolated from HNSCC at sites outside the oropharynx, its role in 
carcinogenesis is much less certain. High-risk HPV is potentially associated with the development of 
a small subset of oral and laryngeal SCCs [5, 15], although the probability of a HPV-attributable 
cancer at these sites is at least five times lower than of SCCs occurring in the oropharynx [13].  A 
number of studies have investigated the prevalence of HPV at other HNSCC sites (excluding 
oropharynx), with widely varying results, potentially as a result of different geography, genetic 
interactions and differing methodology employed [14-16].  
 
A meta-analysis in 2014 has identified a HPV-DNA prevalence of 24% in the oral cavity, and when 
this is combined with p16INK4a status and E6/E7 mRNA the attributable fractions of disease are 7% 
and 16% respectively [2]. Similarly for laryngeal and hypopharyngeal SCC (combined), a HPV-DNA 
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prevalence of 22% was identified, with attributable fractions of 19% when combined with p16INK4a 
positivity, and 9% when combined with E6/E7 mRNA [2]. These findings were correlated with a 
systematic review [15]. There is discrepancy between HPV-DNA prevalence and attributable fraction 
of disease, and the use of E6/7 mRNA analysis to confirm biologically active HPV infection has been 
utilized [2, 16]. It is clear that the presence of HPV DNA in a tumor does not signify that the tumor 
has been caused by HPV [2, 5, 15]. This has contributed to the theory that oncogenic HPV infection 
can sometimes be a ‘bystander’ infection, without contributing to carcinogenesis in a subset of the 
population.  
 
1.2.3 Prognosis  
Prognostic factors in head and neck cancer include the tumour stage (T4) and nodal stage (N2b-3) at 
diagnosis, pack year history of smoking, poor performance status, and HPV status of the tumour [6, 
17]. Overall, HPV-positive tumours in the oropharynx have an improved survival rate when 
compared with HPV-negative tumours, regardless of the treatment modality employed: 75% 3-year 
survival rate compared with 50% in HPV-negative tumours [1, 6, 8]. These patients also demonstrate 
a lower rate of recurrence (approximately 50% lower than HPV-negative tumours), and a lower rate 
of metastatic disease [1, 6]. This has been postulated to be due to the patient’s overall younger age at 
diagnosis, improved functional status and lower rates of morbidities usually associated with higher 
rates of substance abuse [1]. While an underlying molecular mechanism has not been identified yet, 
this remains possible. To date, no association between the presence of HPV and prognosis has been 
demonstrated outside of the oropharynx [5, 15]. Unfortunately, approximately 20% of HPV-positive 
tumours in the oropharynx (those staged as T4 or N3 at diagnosis) do not have a favourable prognosis, 
and have a higher rate of metastatic and recurrent disease [1, 8, 18, 19].  
 
1.2.4 Treatment 
Presently, therapeutic interventions for HNSCC patients include a combination of surgery, 
radiotherapy, chemotherapy and targeted molecular therapies [6]. Despite the differences observed 
clinically between tumours associated with traditional risk factors and those related to HPV, clinical 
guidelines distinguishing treatment strategies between these two patient cohorts do not exist 
currently. The therapeutic options for each patient are determined by a multi-disciplinary team, which 
takes into consideration the stage at diagnosis, HPV status of the tumour and tumour site; as well as 
the patient’s functional status and wishes [4]. Consideration of the expected functional outcomes, 
including the level of organ preservation, and the patient’s quality of life is also important. Early-
stage (T1-2) tumours are usually treated with single modality therapy, such as surgery or radiotherapy 
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alone. More locally advanced, recurrent or metastatic tumours are treated with a combination of 
therapies such as surgical resection followed by post-operative radiotherapy (possibly combined with 
chemotherapy) or concomitant chemo-radiotherapy primarily; with surgical resection reserved for 
residual disease [4]. 
 
As HPV-related oropharyngeal tumours have an overall improved prognosis, focus is increasingly 
shifting towards differential therapeutic regimens for HPV-positive and HPV-negative tumours. It 
has been well established that HPV-positive tumours have an improved responsiveness to 
chemotherapy and radiotherapy treatment regimens, when compared with other treatment modalities 
[1, 4, 6, 8]. Surgical excision of small (T1-2) primary oropharyngeal tumours has been shown to have 
oncologic outcomes equivalent to primary radiotherapy in properly selected patients [20, 21]. 
Contention exists in the literature regarding the appropriateness of de-intensification of therapy for 
HPV-positive tumours given their better survival rates, with the intent of minimizing the morbidity 
associated with treatment [1, 6]. However, it will be increasingly important for clinicians to be able 
to distinguish the subset of patients with HPV-positive tumours who are candidates for therapeutic 
de-escalation but will have a poorer prognosis, so that the offered treatments can be appropriately 
potent.  
 
1.3 Human Papillomavirus 
1.3.1 Structure 
Human papillomaviruses are non-enveloped, double-stranded DNA viruses of the Papillomaviridae 
family, with a genome of approximately 8000bp [1, 22]. There are over 200 distinct HPV genotypes, 
which are divided into high- and low-risk groups based on their demonstrated oncogenic potential [8, 
16, 23]. Low-risk HPVs include Type 6 and 11, which may cause anogenital warts or laryngeal 
papillomas respectively [16, 23]. The most common oncogenic HPV is Type 16, followed closely by 
18 [8, 16, 23]. Others which have demonstrable ability to cause cancer of the cervix, head and neck, 
and anogenital regions include Types 31, 33, 35, 45, 51, 52 and 56 [8, 16, 23]. The mucosal HPV 
genome (Refer to Figure 1) encodes six early proteins (E1-2 and E4-7), two late proteins (L1, L2), 
and a non-coding control region [16]. Across papillomaviruses, L1-2 and E1-2 are well conserved, 
containing genes involved in replication and viral packaging; whereas there can be significant 
variability in the remaining genes, which function in cell cycle entry, viral release and host immune 
evasion [23].  
 
HPVs are transmitted through mucosal and non-mucosal skin epithelium via small tears which allow 
the virus access to the basal layer of the epithelium, where cell infection is followed by a period of 
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genome amplification. Through the E6 and E7 proteins, oncogenic HPVs are able to control entry 
into the cell cycle, which is necessary for completion of its lifecycle [1, 22, 23]. The virus takes 
advantage of the cell differentiation and proliferation between the basal and upper layers of the 
epithelium in order to achieve this. 
 
 
Figure 1.1: Schematic version of the Human Papillomavirus genome (Adapted from [24]) 
 
1.3.2 Natural history 
HPV has been extensively studied in the context of cervical carcinoma in women, and its transmission 
in the genitals by sexual contact has been firmly established [1, 12]. The natural history of HPV 
infection in healthy oral mucosa is the subject of ongoing research. In a healthy Australian population, 
the estimated point prevalence of high-risk HPV was 2.3% (7/307 participants), and the majority of 
infections were HPV-18 [25]. The presence of HPV was significantly associated with male gender, 
and sexual behaviors such as increased number of oral sexual partners [25]. The HIM study [26] has 
demonstrated an incidence of 1.7% of oncogenic HPV infections in healthy oral mucosa; and Gillison 
et al also corroborated these results, finding an overall prevalence of HPV infection in the oral cavity 
of 6.9%, with a higher prevalence in men than women [27].  
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There is increasing evidence that changing sexual behaviors is associated with the rising incidence of 
HPV-associated HNSCC, and subsequently for oral-oral and genital-oral transmission routes [1, 5]. 
For example, oral HPV infection is strongly correlated with sexual practices including ever having 
had oral sex, increased lifetime number of sexual partners, French kissing, history of casual sex and 
younger age at sexual debut [1, 5, 27]. Additionally, both patients with cervical carcinomas and their 
partners have been identified to have a higher risk of developing a future head and neck cancer [1, 
28]. 
 
Given that HPV infection persistence is necessary in the development of cervical cancer, it is likely 
that this is important for HPV-mediated carcinogenesis in the oropharynx as well. The majority of 
oral HPV infections clear spontaneously, with 66% clearing within 12 months and 90% clearing 
within 24 months [1, 26, 27]. The natural history of HPV infection in the oral cavity therefore appears 
to be of shorter duration than in the cervix, and it is clear that oral HPV infection is frequently cleared, 
and does not always result in malignancy [5, 26]. However, the presence of an oral HPV infection 
has been associated with a five- to fifty-fold increased risk of developing a future HNSCC [1, 27]. 
Unanswered question still remain regarding which patients with oncogenic oral HPV infections will 
go on to develop a cancer, and why. While the fraction of patients that will develop HPV-associated 
HNSCC is small, it remains feasible that prophylactic HPV vaccination may prevent the majority or 
all of these cancers from developing if given prior to viral exposure.  
 
1.3.3 Oncogenic pathways of HPV oncoproteins  
HPV encoded E6 and E7 proteins are the dominant oncoproteins, and act via their effects on the p53 
and pRB cellular pathways respectively (Refer to Figure 2). p53 is a well-studied transcription factor 
which induces apoptosis or cell-cycle arrest in response to cellular damage, and is mutated in many 
human cancers, with resultant carcinogenic effects. HPV-E6 binds to E6AP (E6-associated protein), 
and this complex ubiquitinates p53, resulting in its degradation [16]. This then results in prevention 
of cell-cycle arrest and/or apoptosis [16]. E6 also interacts with molecules involved in the extrinsic 
apoptosis pathway, such as Fas-associated Death Domain (FADD), resulting in their degradation, and 
as a result prevents apoptosis [1]. pRB binds the transcription factor E2F, to control progression of 
the cell-cycle through the G1-S checkpoint [16]. HPV-E7 interacts with and destabilizes pRB, causing 
release of E2F and subsequent uncontrolled progression through the cell cycle. Inactivation of pRB 
also indirectly results in over-expression of p16INK4a, a commonly used marker in clinical practice for 
the presence of oncogenic HPV [5, 16].  
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Figure 1.2: Schematic version of E6 and E7 interactions with TP53 and pRB (Adapted from [29]) 
 
1.4 MicroRNAs 
1.4.1 Introduction 
MiRNAs were first discovered in Caenorhabditis Elegans where lin-4 and let-7 were found to control 
timing of larval development [30], and since have been discovered in both plant and animal cells as 
highly-specific tissue biomarkers [31]. They are short (18-25 nucleotide), regulatory, non-coding 
single strands of RNA,  which have diverse roles in cellular functions, including: development, 
differentiation, proliferation, inflammation, immune responses, stress responses, and apoptosis [32, 
33]. MiRNAs were initially linked to human cancers because of their proximity to chromosomal 
breakpoints or areas of instability, and dysregulated expression levels in several human cancers [31]. 
Altered expression of specific miRNAs have been associated with initiation or prognosis in a number 
of human cancers, and functional studies performed in cancer cell lines, or mouse models, involving 
over-expression or knock-down of miRNAS, have supported a role for miRNAs in carcinogenesis 
[31, 34].  
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1.4.2 Nomenclature 
The Faculty of Life Sciences at the University of Manchester, United Kingdom, now hosts and 
maintains miRBase, a searchable database of all published miRNA sequences and annotations [35-
39]. The latest version of this database was released in 2015 (version 21); which contains 1881 
precursors and 2588 mature miRNAs. MiRNAs are identified using the prefix ‘miR’, followed by a 
specific number. As miRNAs exist in three forms during their biogenesis, the prefix can be slightly 
altered to reflect the stage of development: primary miRNA transcript (‘pri-miR’), stem-loop 
precursor miRNA transcript (‘pre-miR’) and mature miRNA (‘miR). The species to which the 
miRNA belongs is designated by three letters which precedes the ‘miR’ prefix: in Homo Sapiens this 
is ‘hsa’.  
 
The numbering of miRNAs is sequential with regards to when they were discovered. Numbered 
suffixes are utilised to denote distinct precursor sequences which express identical mature sequences: 
for example, hsa-miR-16-1 and hsa-miR-16-2. Lettered suffixes identify sequences which are closely 
related and differ by several nucleotides only: for example, hsa-miR-20a and hsa-miR-20b [40]. As 
miRNA terminology and naming has evolved over the years, each miRNA sequence entry in 
miRBase also has a unique accession number, which remains constant and allows changes to be 
tracked in the database, providing the user with full access to the history.  
 
Occasionally there are two miRNA sequences which originate from the same precursor; and 
sequencing technology has indicated that there is usually a dominant sequence, and a secondary 
sequence which originate from opposite arms of the precursor miRNA sequence. Previously these 
have been referred to as miR-142 (dominant) and miR-142* (from opposite arm); however, this has 
shifted to naming each strand for the arm from which it originated: for example: miR-142-3p (from 
the 3’ arm) and miR-142-5p (from the 5’ arm) [35, 39-42].  
 
1.4.3 MicroRNA Biogenesis  
MiRNA biogenesis (Refer to Figure 3) begins with nuclear transcription of a large pri-miRNA, 
transcribed by RNA polymerase II or III [43]. These fold to produce one or more ~80 nucleotide (nt) 
hairpin structures, consisting of a ~32bp imperfect stem loop and large terminal loop [43]. This is 
recognized and processed by two enzymes, RNase III, Drosha (RNASEN) and a double-stranded 
RNA binding protein, Pasha (DGCR8), to form one or more ~60-70nt pre-miRNAs containing ~2nt 
3’ overhangs [31, 44, 45]. These are then actively transported to the cytoplasm by the RAN GTP 
dependent transporter Exportin 5 (XPO5), where they are processed by another RNase III enzyme, 
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Dicer, to yield single-stranded ~22 (16-29) nucleotide structures: the miRNA:miRNA* duplex [31, 
43-45]. Dicer removes the terminal base pairs and loop at the opposite end to the cleavage by Drosha, 
and therefore this defines the second end of the mature miRNA [45].  
 
One strand of the miRNA:miRNA* duplex is then incorporated into a miRNA-containing 
riboucleoprotein complex (miRNP), also referred to as a RNA induced silencing complex (RISC), as 
it is similar in structure and function to the RISC [45]. The miRNA* (antisense strand) is released 
and degraded [45]. This complex contains one member of the Argonaute protein family (Ago 1-4), 
which recognizes and binds the miRNA, regardless of its sequence, and facilitates mRNA target 
recognition [31]. Ago2 is the only argonaute protein in humans which is able to directly cleave target 
mRNAs with near-perfect complementarity [31].  
 
 
Figure 1.3: Schematic version of miRNA biogenesis (Adapted from [44]) 
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1.4.4 MiRNA::mRNA target interaction  
The mRNA target is recognized by base pairing of miRNA nucleotides in positions 2 to 8 (the ‘seed’ 
sequence), to complementary sequences located predominantly in the 3’ UTR or coding regions of 
the target mRNA (Refer to Figure 4) [31, 43, 45]. The fate of the targeted mRNA is dependent on the 
degree of binding complementarity, and can be either mRNA cleavage, or translational repression 
[43]. In humans and other mammalian cells, this pairing is usually with imperfect complementarity, 
resulting in translational repression of the mRNA transcript and mRNA destabilization (e.g. de-
capping, de-adenylation) [31]. In plants, where there is usually pairing with near-perfect 
complementarity, the miRNA will specifically cleave the target mRNA [45]. However, the full extent 
of the mechanistic miRNA::mRNA interactions are not understood at present. There is evidence to 
support alternative modes of miRNA binding (Refer to Figure 4), and it has been estimated that up 
to 40% of miRNA target sites are mediated by non-canonical interactions; indicating that there is far 
more variability in functionally interactive binding sites than previously thought [46].  
 
While the full extent of the mechanistic miRNA interaction with its target mRNA is not understood 
yet, it is estimated that miRNAs are able to regulate the expression of over 90% of human gene 
transcripts. Therefore, they have the potential to significantly influence a vast number of biological 
processes.  
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Figure 1.4: Variations of miRNA::mRNA interactions (Adapted from [46]) 
 
Given the imperfect complementarity of nucleotide matching between miRNAs and their target 
mRNA, one miRNA is able to target many mRNAs (some studies estimate this may be up to 200 per 
miRNA), and in this way miRNAs potentially control an estimated 60% of human mRNAs [44]. It is 
evident that miRNAs are capable of huge effects on cellular functions, and have the potential to 
significantly affect a vast number of biological processes. In addition, miRNAs not only target many 
mRNAs, but also may act cooperatively with other miRNAs to influence a particular cellular 
pathway. Because miRNAs have such a broad influence on cellular processes, deletion or 
amplification of expression is likely to contribute to disease, including cancer [44].  
 
1.4.5 Regulation of miRNA expression 
MiRNA expression is regulated through a number of different mechanisms. Genomic profiling has 
suggested that miRNAs are frequently located in chromosomal areas most involved in alterations in 
human cancer; which therefore potentially influences miRNA expression [31, 47]. Defects in miRNA 
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processing, such as changes in Drosha, Dicer or cofactors involved in biogenesis; as well as altered 
expression of transcription factors, also impact miRNA expression. Epigenetic changes such as 
hyper-methylation or hypo-methylation have also been shown to result in aberrant miRNA 
expression. Complicating this, miRNAs are also able to regulate their own expression through 
negative feedback loops, and regulation of components of the epigenetic machinery [48, 49].  
 
1.5 MicroRNAs in human cancer 
The first indication that miRNAs may be involved in human carcinogenesis came from studies on 
chronic lymphocytic leukaemia (CLL) in 2005, where Calin et al reported down-regulation of miR-
15a and miR-16-1 [50]. More recently, the function of these two miRNAs has been elucidated: 
negative regulation of the BCL2 gene, which functions as an anti-apoptotic gene [44]. MiR-15a and 
miR-16-1 therefore function as tumor suppressors, and their down-regulation in CLL allows for 
unchecked cell cycle progression. MiRNA profiles have demonstrated aberrant miRNA expression 
across a number of tumor types, which are tissue specific, and functional analysis of various 
dysregulated miRNAs through overexpression or silencing has supported their role as either 
oncogenes or tumor suppressors [34, 51, 52]. Further, miRNAs demonstrate hierarchical clustering 
according to developmental origin, and in work by Lu et al, have been used to obtain an accurate 
diagnosis in 12 of 17 patients with metastatic tumors of unknown primary [52] [53].  
 
In addition, genomic mapping has facilitated the identification of loci encoding miRNAs or miRNA 
families. miRNAs that are frequently dysregulated in human cancers tend to be located at or in 
proximity of sites of genomic instability, such as areas of chromosomal breakpoints or deletions [31, 
47]. Common genetic aberrations found in oral cavity SCC, such as amplification of chromosome 
11q13, and loss of distal 11q, have also been associated with altered miRNA expression (such as 
downregulation of miR-125b and miR-100, which map to these regions) [54]. This indicates that 
miRNA expression in cancers may be altered secondary to genetic aberrations occurring in each 
particular cancer, leading to altered miRNA expression profiles and subsequent effects on target 
pathways, promoting carcinogenesis.  
 
1.6 MicroRNAs in head and neck cancer  
1.6.1 Introduction 
Many studies in both head and neck cancer tissue as well as head and neck cancer cell lines have 
investigated miRNA expression profiles of HNSCC (Refer to Table 1.1), and demonstrated aberrant 
expression when compared with normal squamous epithelial tissue. While many different miRNAs 
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have been identified, there are several dysregulations that have been consistent across reported 
studies, and include miR-21, miR-31, miR-106b-25 cluster, miR-155, miR-363 and let-7 (up-
regulated), and miR-125, and miR-375 (down-regulated) [4, 32, 55, 56]. Table 1.1 details the studies 
which have comprehensively profiled miRNA expression in HNSCC. Interestingly, Avissar et al 
identified that the ratio between miR-221: miR-375 had a sensitivity of 92% and specificity of 93% 
when differentiating between normal and tumor tissue in the head and neck, although these results 
have not been further validated to date [57]. 
 
1.6.2 Variations in literature  
Clearly there are differences in the miRNA expression profiles identified by the various studies, and 
variation again in which miRNAs are found to be differentially regulated in HPV-positive and HPV-
negative tumors, as discussed below. This may be due to differing methodology used (microarray, 
next-generation sequencing and quantitative real-time PCR), differences in tumors collected such as 
between anatomical subsites, and the use of HNSCC cell lines versus FFPE tumor tissue or fresh 
frozen tissue, sample size, and differences in analysis of results, including the use of different versions 
of miRBase. The latter may affect results as newer versions of miRBase not only contain novel 
miRNAs, but also include updated sequences of particular miRNAs. There is obvious variation in 
sample type utilized by different studies (cell lines, fresh frozen, FFPE). Several studies [40, 45] 
compared FFPE and fresh frozen tissue with SCC cell lines. Avissar et al [40] found that HNSCC 
cell lines show distinct miRNA clustering, different from that observed in primary tumors, and 
therefore cautioned that cell lines have limited utility as a model for determining clinically relevant 
miRNAs.  
 
 
1.6.3 Differences across subsites  
There is ongoing conflicting evidence regarding whether there are differing expression profiles in 
tumors occurring at different subsites in the head and neck. Hui et al did not identify any difference 
in miRNA expression between HNSCC subsites (oropharynx, hypopharynx, larynx) [55]. Lajer et al 
identified a number of differentially expressed miRNAs across oral cavity and oropharyngeal subsites 
compared with normal tissue, and when comparing oral cavity and oropharyngeal tumors separately, 
although the fold-change in miRNA expression was only moderate, and none of the miRNAs were 
specific to any subsite [58]. However, many of the studies do not comment on site specific miRNA 
differences, making it difficult to assess at this stage whether there are comprehensive differences in 
expression profiles between anatomic subsites or not.  
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Table 1.1: Published studies reporting microRNA alterations in HNSCC according to HPV tumour status 
 
Study Sample size Subsite Normal tissue Tissue type Methodology Up-regulated miRs Down-regulated miRs 
Lajer 2011 30 
19 
Oral cavity 
Oropharynx 
Hypopharynx 
39 Fresh frozen Affymetrix 
miRNA 
microarray 
(miRBase 
v.11) 
qRT-PCR 
miR-195, miR-363 miR-26b,  miR-101, miR-125a, miR-126, miR-127, 
miR-143, miR-145, miR-199a,  miR-199b, miR-
379, miR-381, miR-409, miR-432, miR-433, miR-
517a, miR-1201 
Lajer 2012 46 Oral cavity 
Orophayrnx  
13 Fresh frozen 
FFPE 
Affymetrix 
GeneChip 
miRNA array 
qRT-PCR 
Let-7f, let-7g, miR-15a, miR-15b, miR-16, miR-
20b, miR-21, miR-29a, miR-34a, miR-125b, miR-
146a, miR-146b, miR-150, miR-155, miR-342, 
miR-363, miR-596, miR-598, miR-625, miR-768 
Let-7e, miR-31, miR-99b, miR-125a, miR-181b, 
miR-193b, miR-200c, miR-324, miR-423, miR-
744, miR-877, miR-1189, miR-1275 
Gao 2013 150 Oropharynx  FFPE qRT-PCR miR-9, miR-155 miR-18a, miR-31, miR-223 
Hui 2013 88 Oropharynx 7 FFPE TaqMan low 
density array 
Human 
miRNA panel 
V1.0 
qRT-PCR 
miR-9, miR-20b, miR-422a, miR-492, miR-545, 
miR-591 
miR-107, miR-193b 
Wald 2011 6 Oral cavity 
Oropharynx 
Hypopharynx 
NHOK Cell lines mirVana 
miRNA 
Bioarray V2 
qRT-PCR 
miR-33, miR-363, miR-497 miR-29a, miR-142, miR-155, miR-181a, miR-
181b, miR-218, miR-221, miR-222,  
Miller 2015 53 
357 
 
Oropharynx  FFPE 
FFPE TMA 
Cell lines  
Qiagen 
miRNome 
qPCR 
miR ISH 
miR-9, miR-15b, miR-16-2, miR-20b, miR-25,  
miR-29c, miR-93, miR-106a, miR-106b, miR-107, 
miR-148a, miR-150, miR-222,miR-320a, miR-
335, miR-363, miR-378, miR-598, miR-625,  
miR-126, miR-143, miR-145, miR-193b, miR-
199a, miR-199b, miR-214, miR-337, miR-574 
Mirghani 2016 26 Oropharynx  Fresh frozen 3D-Gene 
human 
miRNA 
microarray 
(Toray 
Industries) 
qRT-PCR 
miR-7-2 miR-18a, miR-18b, miR-99b, miR-107, miR-135b, 
miR-138-1, miR-212, miR-324, miR-584, miR-
615, miR-668, miR-675, miR-857, miR-1234, miR-
1246, miR-3144, miR-3176, miR-3177, miR-4267, 
miR-4418, miR-4764 
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1.6.4 Associations with survival and prognosis  
Several miRNAs have also been correlated with survival and prognosis in HNSCC patients. In a study 
by Gao et al, 6 miRNAs were found to significantly correlate with prognosis: miR-142-3p, miR-146a 
and miR-26b over-expression were associated with improved survival, while miR-31, miR-24 and 
miR-193b over-expression were associated with poorer patient outcome [59]. miR-451 has also been 
identified as significantly over-expressed in HNSCC patients without recurrent disease [55]. Reduced 
expression of miR-137 miR-205 and let-7d has also been significantly associated with increased 
frequency of loco-regional recurrence and poorer overall survival across all subsites [60, 61]. Up-
regulated miR-21 and down-regulated miR-375 have been associated with poorer survival in 
laryngeal SCC [62]. Over-expression of miR-21 in SCC of the tongue has also been associated with 
a poorer prognosis [63]. Further, up-regulation of miR-21 has also been associated with a poorer 5-
year survival rate in HNSCC across all subsites [64]. While it is clear that different studies are 
discovering different miRNAs which are associated with patient outcomes, this nevertheless 
highlights the significance of miRNA expression profiles, and demonstrates a potential future role of 
miRNAs in providing information regarding prognostic outcomes for patients with HNSCC.  
 
Currently, the inability to identify a primary tumor has significant effects on treatment, including a 
wider radiotherapy field, which in turn has significant effects on treatment-associated morbidity [51]. 
Barker et al attempted to classify tumors of unknown primary in six patients, with tumors from base 
of tongue, tonsil and post-nasal space, and found that each tumor maintained its miRNA profile 
between primary site and lymph node metastasis. In addition, the miRNA tumor profile differed 
between each anatomic site, allowing its potential identification through tissue obtained from the 
nodal metastasis [51]. Approximately 10-20% of HNSCC patients have occult metastasis to cervical 
lymph nodes at diagnosis, and this is one of the strongest predictors of prognosis [32, 65]. Using the 
differential expression of miR-205 between HNSCC and normal tissue, Fletcher et al were able to 
distinguish between benign lymph nodes and metastatic SCC to cervical lymph nodes [65]. While 
fine-needle aspiration of a lymph node, in combination with imaging, remains the gold standard of 
metastatic nodal disease detection; miRNAs have potential use as adjunct predictors of nodal disease. 
 
1.7 MicroRNAs in HPV-associated head and neck cancer  
While there are a number of studies into miRNA expression profiles in HNSCC, eight have examined 
HPV as an independent factor (Refer to Table 1). Lajer et al identified an up-regulation in miR-363, 
and down-regulation of miR-125a, miR-126, miR-127-3p, miR-145 and miR-379 which is associated 
with HPV-positive HNSCC in the oropharynx [58]. The same authors compared miRNA expression 
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profiles between HPV positive HNSCC and cervical cancers, and found significant similarity 
between groups, particularly of miR-15, miR-16, miR-195 and miR-497 and families, miR-143, miR-
145 and the miR-106-363 cluster [12]. Gao et al identified five miRNAs which are differentially 
expressed in HPV-positive and HPV-negative oropharyngeal SCCs: miR-9 and miR-155 (up-
regulated), and miR-18a, miR31, and miR-223 (down-regulated) [59]. Differential expression 
between HPV-positive and HPV-negative cell lines has also been demonstrated: miR-33, miR-363 
and miR-497 are up-regulated in HPV-positive HNSCC cell lines; and miR-29a, miR-142, miR-155, 
miR181a, miR-181b, miR-218, miR-221 and miR-222 are down-regulated in HPV-positive HNSCC 
cell lines when compared with HPV-negative lines [66].  
 
1.8 Detection of microRNAs in body fluids  
miRNAs have been isolated from a number of bodily fluids, including saliva, serum, urine, sweat; as 
well as from solid tissues [67]. They are typically present in differing concentrations across the 
tissues, with the highest concentration of miRNAs occurring in saliva, breast milk, seminal fluid, 
tears and plasma; with the most highly expressed miRNAs conserved across fluid types [67]. The 
changes in miRNA expression in body tissue in association with a medical condition such as a 
neoplasm are reflected to varying degrees in accessible body fluids [68, 69]. The most accessible of 
these in HNSCC patients are plasma and saliva. Several studies have focused on miRNA profiling 
saliva of oral cavity tumour patients in the search for a diagnostic tool, with promising results [70, 
71]. Liu and colleagues compared miRNA detection in both plasma and saliva in oral cavity tumours, 
finding expression levels to be higher in saliva [70]. The non-invasive collection of body fluids such 
as saliva for measurement of miRNA expression will provide a useful avenue for miRNA profiling, 
and diagnostic or prognostic tool development, in the future.  
 
1.9 Objectives  
The aims of this project were firstly to compare the expression profile of miRNAs in mucosal head 
and neck squamous cell carcinomas, according to HPV tumour status. Secondly, it aimed to determine 
any variability of miRNA expression in HNSCC in association with lifestyle factors, clinical factors, 
cell cycle regulation or clinical outcomes. The final aim of this project was to investigate potential 
genetic targets for specific miRNAs identified to be differentially expressed, and to link these if 
possible to the biological function of genes known to be dysregulated in HNSCC. 
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CHAPTER TWO: Methodology 
2.1 Ethics approvals  
Ethics approvals were sought and obtained from the University of Queensland (2016001065), the 
QIMR Berghofer Medical Research Institute HREC (1364) and Queensland Health Metro South 
HREC (HREC/11/QPAH/93).  
 
2.2 Participant recruitment and data collection 
Participants included in this study were recruited from a study previously performed [72]. Included 
participants were aged older than 18 years, with a new diagnosis of mucosal head and neck squamous 
cell carcinoma, presenting to the Princess Alexandra Hospital Head and Neck Clinic between 2004 – 
2010. The diagnosis was confirmed with histopathology. Up to date (to January 2017) patient and 
clinical information was obtained from patient records. A total of 240 patients had sufficient tissue 
for inclusion in this study, and one formalin-fixed paraffin-embedded (FFPE) block was available for 
each patient. For the collection of smoking and alcohol consumption data, participants were 
categorised as a non-smoker or drinker (having never regularly consumed the product), current 
(continuing to consume either product) or ex-smoker or drinker (having ceased consumption at least 
six months prior to diagnosis).    
 
2.3 HPV Status and Immunohistochemistry 
HPV (Human papillomavirus) status, type and p16INK4a immunohistochemistry information was 
obtained from a previous study, where the methods are described [72].  
 
2.4 RNA extraction 
Total RNA was extracted from one block of FFPE tissue per patient using the RecoverAll Total 
Nucleic Acid Isolation Kit (ThermoFisher), as described by the manufacturer. MiRNAs have been 
demonstrated to be well preserved in FFPE tissue, and the RecoverAll kit has been shown to be as 
effective in recovering total RNA from FFPE tissue when compared with total RNA extracted from 
fresh frozen tissue [73]. Quality and quantity of RNA was established with the Nanodrop 1000 
Spectrometer (A260/280 >1.9 was taken to indicate RNA purity) and RNA Integrity Number (RIN). 
Total RNA was stored at -80C until further use.  
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2.5 Microarray 
Fifty-two tonsillar SCCs were chosen for the microarray. Oropharyngeal tumours were chosen as 
HPV has the highest prevalence in this subset of tumours. 1g of total RNA for each patient was 
reconstituted in NaOAc (3M, pH 5.2) and 100% ethanol according to the shipping instructions for 
LC Sciences (Texas, USA). The specimens were shipped on dry ice to LC Sciences, where a 
comprehensive miRNA microarray was performed, using miRBase v.21 [37-39], and Cy5 dye colour.  
 
2.6 Selection of microRNAs for further validation  
The top eighteen miRNAs which were differentially expressed between HPV positive and negative 
tumours on the microarray, with a fold change of 2.0, were chosen for further validation in a larger 
cohort of tumours. RNU-48, a small, non-coding RNA molecule, was chosen as the endogenous 
control. RNU-48 is expressed widely in human tissues and is stable; and is widely used as an 
endogenous control for microRNA expression profiling [74]. Further, this molecule has been utilised 
commonly as an endogenous control in the study of microRNA expression in head and neck cancer 
[60, 75, 76], as well as squamous cell carcinoma at other sites such as the lung [77].  
 
2.7 Real-Time PCR Validation 
The following steps were performed for all specimens. TaqMan assays (Life Technologies) 
combined with a sensitive method of detection (Fluidigm, HD Biomark) was used. cDNA synthesis 
was performed with a mastermix composed of 6.75L of a custom TaqMan RT primer pool 
(composed of 10L each RT primer probe (5X) and 820L 1xTE), 0.34L dNTP, 1.69L 10X RT 
buffer, 1.125L Multiscribe, and 3.38L Nuclease-free water). The RT primers included were 
miRNA specific RT primers contained within each TaqMan Assay. These were: hsa-miR-15a-5p 
(000389), hsa-miR-15b-5p (000390), hsa-miR-16-2-3p (002171), hsa-miR-20b-5p (001014), hsa-
miR-29a-3p (002112), hsa-miR-29c-3p (000587), hsa-miR-30e-5p (000421), hsa-miR-142-3p 
(000464), hsa-miR-146a-5p (000468), hsa-miR-148b-3p (000471), hsa-miR-150-5p (000473), hsa-
miR-155-5p (002623), hsa-miR-205-3p (241040_mat), hsa-miR-342-3p (002260), hsa-miR-361-3p 
(002116), hsa-miR-363-3p (002171), hsa-miR-3607-3p (463814_mat), hsa-miR-4484 (464264_mat) 
and RNU-48 (001006; FFPE endogenous control). On ice, 3L of total RNA (concentration of 
20ng/L) and 12L mastermix were added to a 96-well plate. In a  S100 Thermal Cycler (BioRad), 
the plate was incubated at 16C for 30mins, 42C for 30 mins and 85C for 5 mins. The plate was 
placed on ice and then stored at -20C.  
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Preamplification was performed on a 384-well plate on ice. 2.5L cDNA and 7.5L of mastermix 
were added to each well. The mastermix was composed of 1.69L of assay probe pool (composed of 
10L each assay probe (20X) and 820L 1xTE), 5.63L preamp mastermix and 1.125L nuclease-
free water. On a BioRad PCR machine, the plate was incubated at 95C for 10 mins, 55C for 2 mins, 
72C for 2 mins, 14 cycles of 95C for 15s and then 60C for 4 mins; followed by 99.99C for 10 
mins. The plate was immediately removed and incubated on ice for 5 mins. Each preamp reaction 
was diluted 1:7 with 0.1xTE prior to the Fluidigm reaction.  
 
The assay wells of the Fluidigm plate were prepared with 3L 20X assay probe, and 3L 2X loading 
reagent in each well. Each assay was performed in quadruplicate. Empty wells were prepared with 
3L nuclease-free water and 3L 2X loading reagent. The sample wells of the Fluidigm plate were 
prepared with 2.7L of diluted preamp product, and 3.3L of gene expression mastermix (composed 
of 360L gene expression buffer, and 36L of sample loading reagent). In empty wells, nuclease-
free water replaced the sample.  
 
The Fluidigm plates were primed in the BioMark HX machine, and then each assay and sample mix 
was added to the plate. The plate was replaced in the BioMark HX machine for mixing of assay and 
samples; and then transferred to the BioMark HD machine. ROX was used as a passive reference, 
and FAM-MGB was used as a single probe. The plate was incubated at 50C for 2mins, 70C for 
30mins, 25C for 10mins, 50C for 2mins, and then 95C for 10mins; followed by PCR cycling (40 
cycles) of 95C for 15s and 60C for 1min. PCR data was collected using BioMark HD Data 
Collection software, and analysed using the Fluidigm Real-Time PCR Analysis v.4.0.1 package. A 
serial dilution (30ng, 15ng, 3ng, 0.5ng) of a sample that highly expressed all miRNAs chosen for 
validation was included on each plate to test the limits of detection.  
 
2.8 Median normalisation of Fluidigm data 
Four Ct values were obtained for each microRNA for each sample (between 1 and 40, the number of 
PCR cycles). These were averaged to obtain one averaged Ct value for each microRNA for each 
sample. The median Ct value for RNU-48 was calculated from all Ct values obtained across all 
samples for RNU-48. The median value for RNU-48 Ct values across all samples was 11.60448563.  
Then, the difference between the median Ct value for RNU-48 and the Ct value for RNU-48 for each 
sample were calculated. Finally, this difference was added to each average Ct value for each 
microRNA for each sample. This yielded a Ct value for each microRNA, for each sample, which was 
normalised to the median RNU-48 Ct value. This data was then used for further analysis. This method 
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has been described and utilised previously in studies pertaining to the use of the Fluidigm system for 
analysis of microRNA expression [78, 79].  
 
2.9 Statistical analysis 
The microarray results were analysed using Genespring GX. A Mann-Whitney U-test was performed 
between HPV positive and negative groups to yield differentially expressed miRNAs. Analyses were 
also performed for clinical and pathological factors such as smoking status, recurrence of disease and 
p16INK4a status. Results from Fluidigm IFC real-time PCR were interpreted using the Fluidigm Real-
Time PCR Analysis software, and normalised data was calculated as outlined above in Section 2.8. 
SPSS v.24 was used to analyse the results. The differences between individual groups (univariate 
analysis of each miRNA in each cohort) was assessed using the Mann-Whitney U-test, and adjusted 
for multiple comparisons using the Benjamini and Hochberg method, and ANOVA where 
appropriate. Univariate and multivariate logistic regression were used to determine miRNAs 
associated with disease stage at diagnosis and recurrence. Survival analysis was performed for 
recurrence-free (RFS) and disease-free survival (DFS) with univariate and multivariate cox 
proportional hazard model with forwards covariate search. Analyses were performed for 
oropharyngeal and oral cavity tumours separately, for all subsites combined, and for all non-
oropharyngeal tumours (oral cavity, larynx, hypopharynx).  
 
2.10 MicroRNA target prediction  
2.10.1 Introduction 
As discussed earlier, miRNAs function by targeting and inhibiting specific mRNAs. Given the 
imperfect complementarity in miRNA:mRNA binding in mammalian cells, an enormous number of 
potential target binding sites exist for each miRNA. Computational approaches for miRNA target site 
prediction are utilised in this context to limit the potential target genes for laboratory validation, as 
this can be expensive and laborious.  Computational databases for miRNA target site prediction are 
notoriously lacking in sensitivity and specificity, and although each algorithm has predictive power, 
each has limitations based on inclusion or exclusion of features which may predict target sites [80]. 
Combining multiple prediction tools can overcome the limitations of use of a solitary algorithm, and 
is currently the best method for target identification and prediction [80, 81].  
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2.10.2 Methodology 
In this study, a combination of the three most frequently updated and used online target prediction 
algorithms were utilised, TargetScan (version 7.1), DIANA-microT-CDS (version 5.0) and 
miRANDA-mirSVR (2010 Release). The specifics of each individual database will be further 
discussed below. Only predicted targets identified across all three online databases were considered 
possible targets. Each online algorithm was mined and sequentially filtered for potential target genes 
for each miRNA. A combination of scores from each database was utilized to give a final score for 
each predicted target gene. A further list of potential target genes was obtained from miRSystem 
(version 20160513), an online database which searches seven different online target prediction 
algorithms and condenses the results [82]. This list was limited to target genes identified across at 
least three algorithms. 
 
Both the list of top twenty predicted gene targets for each miRNA and the full list of putative targets 
identified across at least three algorithms in miRSystem were utilised for further network analysis, 
using both the Database for Annotation, Visualisation and Integrated Discovery (DAVID; version 
6.8) and Ingenuity Pathway Analysis (IPA, Qiagen). MiRTarBase [83] was also interrogated for 
genes identified in the present study as the top twenty predicted targets, to identify those which have 
already been experimentally validated.   
 
2.10.3 TargetScan 
The TargetScan database was one of the first online computational methods for use in the 
identification of potential target mRNA:miRNA interactions, and is well maintained with the most 
recent update in 2015 [81]. This algorithm utilises a total context score (total context ++) based on 
14 features. These include miRNA factors such as the PCT score, or probability of conserved targeting, 
estimates the probability of a site being conserved due to targeting by a miRNA; seed-pairing stability 
(SPS), which predicts thermodynamic stability of pairing to the seed sequence; target site type; local 
AU content; minimum distance from the stop codon; predicted structural accessibility (SA); 3’ 
supplementary pairing and target site abundance in the 3’ UTR [84]. Predicted target mRNA factors 
are also considered by the algorithm, including length and number of sites in the 3’ UTR and ORF 
[84]. The aggregate PCT score is provided as one 3’ UTR may contain multiple potential target sites 
[80, 84]. The main limitations of TargetScan currently include that the algorithm is focused to detect 
targets in the 3’UTR region of mRNA transcripts, and therefore does not include potential binding 
sites elsewhere in the target mRNA, and at the present time does not include alternative isoforms of 
target 3’ UTRs [81, 84].  
22 | 97 
 
2.10.4  miRANDA-mirSVR 
The miRanda-mirSVR algorithm additionally was one of the earlier online target prediction tools, 
and was last updated in 2010 [80, 85, 86]. In this algorithm, miRanda identifies 3’ UTR binding sites 
and complementarity in binding, and predicts the free energy of a mRNA:miRNA interaction. 
Conservation of both the binding site and position in 3’ UTR sequence is also taken into account. The 
mirSVR algorithm is then used to score potential duplexes, and includes a number of other factors 
such as target site accessibility, AU flanking content, position of target site, base pairing, conservation 
and 3’ UTR length [80, 85]. Additionally, the advantage to this predictive algorithm is that it takes 
into account the strength of a miRNA’s regulatory or repressive effect on a potential target mRNA 
[80, 81, 85, 86].  
 
2.10.5  DIANA-microT-CDS 
The DIANA-microT-CDS database is the latest version of another of the first online miRNA target 
prediction tools, and was most recently updated in 2012 [80, 87]. This algorithm takes into account 
both potential binding sites located in the 3’UTR as well as in coding regions (CDS), and currently 
remains the only online database to do so [80, 81]. The inclusion of CDS binding sites significantly 
increases the sensitivity of the obtained dataset [88]. Other features contained in the analysis include 
accessibility of target sites; binding category weight, an estimate of the efficacy of binding in an 
extended seed sequence; conservation; paired stability; distance to adjacent binding sites; AU content; 
and the predicted free energy of the mRNA:miRNA binding [80, 81]. The algorithm uses individual 
models for binding sites in each 3’ UTR and CDS, and then combines them into a single score.  
 
2.11 Gene ontology and gene network analysis  
For each miRNA, the Database for Annotation, Visualisation and Integrated Discovery (DAVID; 
version 6.8) was interrogated using the list of putative target genes obtained from miRSystem for 
both gene ontology analysis and functional enrichment of gene clusters. Gene ontology aims to 
describe gene functions and unify the relationships between these concepts, with three aspects. These 
include molecular functions, or the molecular activities of a gene; and biological activities, such as 
the larger pathways which are composed of multiple functions and genes. For this analysis, Homo 
Sapiens was used as the species and background. A p value of <0.0001 was considered significant 
for over-represented functions. Functional gene classification was also performed using DAVID. The 
list obtained from miRSystem for each miRNA, as well as the list of top gene targets identified in the 
previous study, were classified into functionally enriched gene clusters. This was performed using 
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Homo Sapiens as the species and background, and the highest stringency filter. An enrichment score 
of 2.0 was considered to be significantly enriched.  
 
Ingenuity Pathway Analysis (IPA, Qiagen) was then used to interrogate the list of putative target 
genes, including both the top twenty predicted targets identified, and a full list of predicted targets 
obtained from miRSystem, for the top gene networks targeted. This software transforms a list of 
genes into a large network, which optimizes interconnectivity between a set of user-specific genes, 
which may represent significant biological functions. The significance of a particular pathway is 
identified with a Fischer’s Exact Test, and a p value of <0.05 was considered statistically significant. 
Up-stream regulators of these pathways were noted, as was interactions with canonical pathways. 
The genes involved in the top twenty-five target gene networks identified were interrogated for the 
genes identified in the top twenty miRNA targets in the present study. 
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CHAPTER THREE: MiRNA Profiling 
3.1 Patient characteristics and HPV status 
A summary of patient and tumour characteristics, separated by HPV status, are presented in Table 
3.1. A total of 240 patients had sufficient tissue for RNA extraction and were included in this study. 
Forty-six of the tumours were HPV positive, and the highest prevalence of HPV was in the 
oropharynx (n=36, p<0.0001). All HPV-positive tumours contained oncogenic HPV types. The 
majority of HPV positive tumours expressed HPV-16 (n=38), followed in frequency by HPV-18 
(n=5), HPV-33 (n=2) and HPV-69 (n=1). The majority of patients with HPV positive tumours were 
younger than those with HPV-unrelated tumours. In both groups, the majority of patients were male, 
and current or ex-smokers and consumers of alcohol. As expected, a strong correlation existed 
between p16INK4a (p<0.0001) and Cyclin D1 (p<0.0001) status in HPV-associated tumours. HPV-
positive tumours tended to present at clinically more advanced nodal stages than their HPV-negative 
counterparts (p<0.0001). HPV-negative tumours had higher rates of recurrence of the primary tumour 
and overall poorer survival than the HPV-associated tumours included in this study [72].  
 
Table 3.1: Patient and tumour characteristics of HPV-positive and negative tumours 
Characteristics HPV Negative 
n (%) 194 
HPV Positive 
n (%) 46 
P value 
Age 
<40 years 
40-49 years 
50-59 years 
60-69 years 
70-79 years 
>80 years 
 
5 (2.6%) 
21 (10.8%) 
52 (26.8%) 
49 (25.3%) 
47 (24.2%) 
20 (10.3%) 
 
3 (6.5%) 
7 (15.2%) 
24 (52.2%) 
9 (19.6%) 
2 (4.3%) 
1 (2.2%) 
 
0.0010 
Gender 
Male 
Female 
 
138 (71.1%) 
56 (28.9%) 
 
40 (87.0%) 
6 (13.0%) 
 
0.0275 
Smoking 
Non-smoker 
Current smoker 
Ex-smoker 
 
19 (10.0%) 
105 (55.3%) 
66 (34.7%) 
 
6 (13.0%) 
16 (34.8%) 
24 (52.2%) 
 
0.0427 
Alcohol 
Non-drinker 
Current drinker 
Ex-drinker 
 
18 (9.9%) 
146 (80.2%) 
18 (9.9%) 
 
5 (11.1%) 
35 (77.8%) 
5 (11.1%) 
 
0.9356 
Tumour site 
Oral cavity  
Oropharynx  
Larynx  
Hypopharynx  
 
83 (42.8%) 
39 (20.1%) 
52 (26.8%) 
20 (10.3%) 
 
5 (10.9%) 
36 (78.3%) 
3 (6.5%) 
2 (4.3%) 
<0.0001 
Tumour differentiation 
Well 
Mod 
Poor 
 
26 (14.1%) 
106 (57.6%) 
52 (28.3%) 
 
1 (2.3%) 
23 (53.5%) 
19 (44.2%) 
 
0.0300 
Recurrence 
Yes 
No 
Not stated 
 
63 (36.0%) 
106 (60.6%) 
1 (0.6%) 
 
5 (11.6%) 
38 (88.4%) 
0 (0.0%) 
 
0.0167 
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Other 
N/A 
1 (0.6%) 
4 (2.2%) 
0 (0.0%) 
0 (0.0%) 
T Stage 
T1 
T2 
T3 
T4 
 
44 (22.9%) 
51 (26.6%) 
36 (18.7%) 
61 (31.8%) 
 
14 (31.1%) 
16 (35.6%) 
4 (8.9%) 
11 (24.4%)  
0.1880 
N Stage 
N0 
N1 
N2 
N3 
 
114 (59.4%) 
22 (11.5%) 
51 (26.5%) 
5 (2.6%) 
 
7 (15.5%) 
7 (15.5%) 
27 (60.0%) 
4 (9.0%) 
<0.0001 
M Stage 
M0 
M1 
Mx 
 
187 (99.0%) 
1 (0.5%) 
1 (0.5%) 
 
43 (100.0%) 
0 (0.0%) 
0 (0.0%) 
0.7949 
Disease status at last follow-up 
Alive without disease 
Alive with disease 
Dead without disease 
Dead with disease 
Lost to F/U 
 
80 (41.3%) 
7 (3.6%) 
5 (2.6%) 
67 (34.5%) 
35 (18.0%) 
 
32 (69.6%) 
2 (4.3%) 
0 (0.0%) 
5 (10.9%) 
7 (15.2%) 
0.0033 
p16 status 
Positive 
Negative 
 
19 (10.7%) 
159 (89.3%) 
 
41 (89.1%) 
5 (10.9%) 
 
<0.0001 
Cyclin D1 status 
Positive 
Negative 
 
175 (97.2%) 
5 (2.8%) 
 
35 (79.5%) 
9 (20.5%) 
 
<0.0001 
 
3.2 Microarray results 
The microarray (performed for fifty-two oropharyngeal tumours) found a significant difference in 
miRNA expression between HPV positive and negative tumours, as defined by HPV DNA positivity 
in the tumour (Refer to Figure 3.1 and Table 3.2). Seventeen miRNAs were differentially expressed 
in HPV DNA positive tumours, with a fold change (FC) of >2.0 (p < 0.001). Six of these retained 
their significance with a p < 0.0001: hsa-miR-16-2-3p, hsa-miR-146a-5p, hsa-miR-150-5p, hsa-miR-
155-5p, hsa-miR-342-3p and hsa-miR-3607-3p. Eighteen miRNAs were also identified to be 
differentially expressed between tumours that were HPV DNA/p16INK4a positive and those that were 
HPV DNA/p16INK4a negative (Refer to Table 3.3). Differential miRNA expression was also identified 
between smokers and non-smokers (Refer to Supplementary Table 3.4), patients who had recurrence 
of the primary tumour (Refer to Supplementary Table 3.5) and with p16INK4a status (Refer to 
Supplementary Tables 3.2 and 3.3).  
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Table 3.2: Differential microRNA expression in HPV DNA positive oropharyngeal tumours observed 
on microarray (Fold change >2.0, p <0.001). Seventeen miRNAs were differentially expressed in 
HPV DNA positive tumours, one down-regulated, and sixteen up-regulated.  
 
miRNA FC P value Direction 
hsa-miR-142-3p 9.87 3.54E-4 Up 
hsa-miR-142-5p 8.77 1.49E-4 Up 
hsa-miR-16-2-3p 8.73 3.70E-5 Up 
hsa-miR-363-3p 7.42 1.65E-4 Up 
hsa-miR-361-3p 7.12 2.95E-4 Up 
hsa-miR-150-5p 6.55 2.10E-5 Up 
hsa-miR-205-3p 6.50 7.93E-4 Up 
hsa-miR-15a-5p 5.64 1.26E-4 Up 
hsa-miR-155-5p 4.13 5.82E-6 Up 
hsa-miR-342-3p 3.74 9.47E-6 Up 
hsa-miR-146a-5p 3.06 3.12E-6 Up 
hsa-miR-4484 3.06 6.44E-4 Down 
hsa-miR-29a-3p 2.75 3.90E-4 Up 
hsa-miR-15b-5p 2.67 2.80E-4 Up 
hsa-miR-30e-5p 2.60 3.90E-4 Up 
hsa-miR-3607-3p 2.39 5.72E-5 Up 
hsa-miR-16-5p 2.21 2.61E-4 Up 
 
  
27 | 97 
Table 3.3: Differential microRNA expression in HPV DNA and p16INK4a positive oropharyngeal 
tumours observed on microarray (Fold change >2.0, p <0.01). Eighteen miRNAs were differentially 
expressed in positive tumours, one down-regulated, and seventeen up-regulated.  
 
miRNA FC P value Direction 
hsa-miR-15a-5p 5.66 4.42E-4 Up 
hsa-miR-16-2-3p 7.44 1.02E-4 Up 
hsa-miR-16-5p 2.10 0.001 Up 
hsa-miR-29a-3p 2.74 7.10E-4 Up 
hsa-miR-29c-3p 4.30 4.73E-4 Up 
hsa-miR-30e-5p 2.53 0.001 Up 
hsa-miR-142-3p 10.48 2.55E-4 Up 
hsa-miR-142-5p 7.14 4.97E-4 Up 
hsa-miR-146a-5p 2.87 1.88E-5 Up 
hsa-miR-150-5p 7.23 1.21E-5 Up 
hsa-miR-155-5p 4.14 5.88E-6 Up 
hsa-miR-342-3p 3.33 9.24E-5 Up 
hsa-miR-342-5p 4.04 0.001 Up 
hsa-miR-361-3p 6.94 1.69E-4 Up 
hsa-miR-363-3p 6.13 3.71E-4 Up 
hsa-miR-3607-3p 2.40 6.16E-5 Up 
hsa-miR-3653-5p 5.18 3.56E-4 Up 
hsa-miR-4484 2.72 0.001 Down 
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Figure 3.1: Heat map corresponding to Table 3.2 visually demonstrating the difference in miRNA 
expression between HPV positive (blue) and negative (red) tumours in the oropharynx, with a fold 
change of >2.0 (p<0.0001). Up-regulated microRNAs are designated red, and down-regulated 
microRNAs are designated green.  
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3.3 Validation of microRNAs 
A larger patient cohort was used to validate the microarray findings, including tumours from all four 
head and neck subsites: oropharynx, oral cavity, larynx and hypopharynx (n = 240). Eighteen 
miRNAs were chosen for further validation: hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-miR-16-2-3p, 
hsa-miR-20b-5p, hsa-miR-29a-3p, hsa-miR-29c-5p, hsa-miR-30e-5p, hsa-miR-142-3p, hsa-miR-
146a-5p, hsa-miR-148b-3p, hsa-miR-150-5p, hsa-miR-155-5p, hsa-miR-205-3p, hsa-miR-342-3p, 
hsa-miR-361-3p, hsa-miR-363-3p, hsa-miR-3607 and hsa-miR-4484. hsa-miR-4484 failed the assay 
quality control, and was therefore not included in any further analyses.  
 
3.3.1 HPV Status  
Between HPV positive and negative tumours, five miRNAs demonstrated differential expression in 
the oropharynx (Refer to Table 3.4). These were: hsa-miR-16-2-3p, hsa-miR-20b-5p, hsa-miR-142-
3p, hsa-miR-150-5p and hsa-miR-363-3p (up-regulated). There was no difference between HPV 
positive and negative tumours at other individual subsites (oral cavity, larynx, hypopharynx). Across 
all HNSCC subsites combined, seven miRNAs were significantly differentially expressed between 
the two groups. These were: hsa-miR-29a-3p, hsa-miR-29c-3p, hsa-miR-148b-3p and hsa-miR-205-
3p (down-regulated), and hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-363-3p (up-regulated).  
 
Table 3.4: Differential microRNA expression between HPV DNA positive tumours across all subsites 
(All), and in the oropharynx (OP) identified on further validation of miRNA expression. 
miRNA HPV Positive 
MnCt (Range) 
HPV Negative  
MnCt (Range) 
P value Log2 Fold 
change 
hsa-miR-16-2-3p 
OP 
All 
 
25.95 (22.40-40.00) 
26.04 (22.40-40.00) 
 
39.31 (23.67-40.00) 
32.03 (20.90-40.00) 
 
0.0069 
ns 
 
13.36 
hsa-miR-20b-5p 
OP 
All 
 
19.91 (16.20-29.64) 
19.86 (16.20-29.64) 
 
21.11 (18.36-37.19) 
20.48 (12.96-39.57) 
 
0.0016 
ns 
 
1.20 
hsa-miR-29a-3p 
OP 
All 
 
12.67 (10.25-14.83) 
12.70 (10.10-14.83) 
 
12.64 (10.43-15.84) 
11.72 (2.80-23.70) 
 
ns 
<0.0001 
 
 
-0.98 
hsa-miR-29c-3p 
OP 
All 
 
22.03 (18.13-29.64) 
21.96 (18.04-29.64) 
 
20.82 (18.39-40.00) 
20.36 (8.30-37.19) 
 
ns 
<0.0001 
 
 
-1.60 
hsa-miR-142-3p 
OP 
All 
 
14.62 (12.05-19.75) 
15.38 (11.69-19.75) 
 
16.54 (12.83-22.56) 
15.79 (7.52-27.87) 
 
0.0006 
0.0397 
 
1.92 
0.41 
hsa-miR-148b-3p 
OP 
All 
 
24.54 (21.19-37.65) 
24.54 (21.19-34.05) 
 
24.75 (20.50-40.00) 
23.48 (17.04-40.00) 
 
ns 
0.0363 
 
 
-1.06 
hsa-miR-150-5p 
OP 
All 
 
10.49 (9.03-13.55) 
10.67 (8.30-13.58) 
 
11.52 (8.16-15.41) 
11.64 (1.78-26.13) 
 
0.0117 
0.0039 
 
1.03 
0.97 
hsa-miR-205-3p 
OP 
 
24.10 (19.53-37.06) 
 
24.60 (18.57-40.00) 
 
ns 
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All 24.04 (21.29-37.06) 22.67 (12.93-40.00) 0.0043 -1.37 
hsa-miR-363-3p 
OP 
All 
 
25.61 (22.41-40.00) 
25.68 (22.41-40.00) 
 
37.20 (22.45-40.00) 
28.53 (16.20-40.00) 
 
0.0004 
0.0304 
 
11.59 
2.85 
 
 
3.3.2 Analysis of HPV DNA status and p16 INK4a status 
In the oropharynx, seven miRNAs were differentially expressed in HPV DNA positive and p16INK4a 
positive tumours as compared with HPV DNA negative and p16INK4a negative tumours. These were: 
hsa-miR-15b-5p, hsa-miR-16-2-3p, hsa-miR-20b-5p, hsa-miR-30e-5p, hsa-miR-142-3p, hsa-miR-
361-3p and hsa-miR-363-3p, and were all up-regulated in HPV DNA and p16INK4a positive tumours 
(Refer to Table 3.5). Across all subsites, only four miRNAs were significantly differentially 
expressed: hsa-miR-16-2-3p, hsa-miR-20b-5p (up-regulated), hsa-miR-29a-3p and hsa-miR-29c-3p 
(down-regulated). There was no difference observed at other subsites of the head and neck (oral 
cavity, larynx and hypopharynx).  
 
Table 3.5: Differential microRNA expression between HPV DNA positive and p16INK4a positive 
tumours across all subsites (All) and in the oropharynx (OP) identified on further validation of 
miRNA expression.  
miRNA HPV Positive  
MnCt (Range) 
HPV Negative  
MnCt (Range) 
P value Fold change 
(Log2) 
hsa-miR-15b-5p 
OP 
All 
 
17.04 (14.69-29.64) 
17.23 (14.69-29.64) 
 
17.85 (15.67-21.28) 
17.33 (8.79-27.21) 
 
0.0249 
ns 
 
0.80 
hsa-miR-16-2-3p 
OP 
All 
 
24.61 (22.40-40.00) 
25.91 (22.40-40.00) 
 
39.73 (23.67-40.00) 
35.64 (16.36-40.00) 
 
0.0008 
0.0126 
 
15.11 
9.73 
hsa-miR-20b-5p 
OP 
All 
 
18.80 (16.20-29.64) 
19.12 (16.20-29.64) 
 
21.26 (18.36-37.19) 
20.36 (11.42-39.57) 
 
<0.0001 
0.0187 
 
2.45 
1.24 
hsa-miR-29a-3p 
OP 
All 
 
12.46 (10.25-14.83) 
12.67 (10.25-14.83) 
 
12.69 (10.43-15.84) 
11.60 (2.80-23.70) 
 
ns 
0.0406 
 
 
-1.09 
hsa-miR-29c-3p 
OP 
All 
 
21.57 (18.13-29.64) 
21.61 (18.13-29.64) 
 
20.79 (18.62-40.00) 
20.41 (8.30-40.00) 
 
ns 
0.0104 
 
 
-1.18 
hsa-miR-30e-5p 
OP 
All 
 
18.89 (17.48-29.64) 
18.97 (17.08-29.64) 
 
20.69 (17.27-40.00) 
19.38 (11.75-40.00) 
 
0.0121 
ns 
 
1.80 
hsa-miR-142-3p 
OP 
All 
 
13.76 (12.05-17.62) 
14.08 (11.69-19.29) 
 
16.48 (12.83-22.56) 
15.74 (7.52-27.87) 
 
0.0005 
ns 
 
2.72 
hsa-miR-361-3p 
OP 
All 
 
24.79 (21.27-40.00) 
25.12 (21.27-40.00) 
 
27.50 (22.06-40.00) 
25.64 (12.61-40.00) 
 
0.0456 
ns 
 
2.70 
hsa-miR-363-3p 
OP 
All 
 
25.13 (22.41-40.00) 
25.68 (22.41-40.00) 
 
37.20 (22.45-40.00) 
28.46 (16.20-40.00) 
 
0.0027 
ns 
 
12.07 
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3.3.3 Cell cycle regulation factors 
There was no difference in miRNA expression between p16INK4a positive and negative specimens in 
any individual subsite of the head and neck. hsa-miR-16-2-3p was significantly differentially 
expressed when all subsites were combined (p=0.0351). In the oropharynx, four miRNAs were up-
regulated between tumours positive and negative for Cyclin D1 immunohistochemistry. These were: 
hsa-miR-146a-5p (p=0.0012), hsa-miR-150-5p (p=0.0366), hsa-miR-342-3p (p=0.0454) and hsa-
miR-3607-3p (p=0.038). There was no difference in miRNA expression with Cyclin D1 status across 
all subsites combined. 
 
3.3.4 Lifestyle factors 
Across all subsites, hsa-miR-363-3p expression was significantly up-regulated in non-smokers as 
compared with smokers (p = 0.0032). Several other miRNAs trended towards significantly different 
expression, but this did not achieve statistical significance. These included: hsa-miR-16-2-3p, hsa-
miR-20b-5p, hsa-miR-205-3p and hsa-miR-3607-3p. In the oropharynx alone, hsa-miR-20b-5p was 
significantly differentially expressed between smokers and non-smokers (p<0.0001). In a two-way 
ANOVA comparison of the effect of HPV status and smoking status on miRNA expression, only hsa-
miR-150-5p (p=0.029) was significantly different in the oropharynx. There was no difference at other 
individual subsites or across all sites.  
 
There was no difference in miRNA expression between patients who consumed alcohol and those 
who abstained at individual and across all subsites. Across all subsites, and in the oral cavity, larynx 
and hypopharynx individually, there was no difference in miRNA expression between HPV positive 
and negative tumours in association with alcohol consumption status. In the oropharynx, a number of 
miRNAs were up-regulated between HPV positive and negative tumours in association with alcohol 
consumption status. These were: hsa-miR-15a-5p (p<0.0001), hsa-miR-20b-5p (p<0.0001), hsa-miR-
29c-3p (p<0.0001), hsa-miR-30e-5p (p<0.0001), hsa-miR-142-3p (p=0.0005), hsa-miR-146a-5p 
(p=0.032), hsa-miR-148b-3p (p=0.011), hsa-miR-155-5p (p=0.041) and hsa-miR-205-3p (p=0.002).  
 
3.3.5 Recurrence of primary tumour 
Irrespective of HPV status, in the oropharynx, down-regulation of hsa-miR-16-2-3p was associated 
with recurrence of the primary tumour (p = 0.0377). Up-regulation of four miRNAs was associated 
with primary tumour recurrence across all four head and neck subsites: hsa-miR-15a-5p (p=0.0247), 
hsa-miR-29a-3p (p=0.0007), hsa-miR-29c-3p (p=0.001) and hsa-miR-3607-3p (p=0.0487). In 
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oropharyngeal HPV positive tumours compared with HPV negative tumours, hsa-miR-205-3p 
(p=0.006), hsa-miR-142-3p (p=0.050) and hsa-miR-363-3p (p=0.044) were up-regulated in HPV 
positive tumour without recurrence. 
 
3.3.6 Stage at diagnosis  
There was no difference observed in miRNA expression with increasing T-stage at diagnosis across 
all subsites, with and without consideration of HPV status.   
 
In the oropharynx, an analysis of HPV status and N-stage found down-regulation of hsa-miR-15b-5p 
(p=0.012) and hsa-miR-342-3p (p=0.009), and up-regulation of hsa-miR-15a-5p (p=0.012), hsa-miR-
30e-5p (p=0.034) and hsa-miR-155-5p (p=0.046) to be significantly associated with increasing N-
stage at diagnosis. Irrespective of HPV-status, increasing N-stage at diagnosis was associated with 
significant up-regulation of hsa-miR-20b-5p (p=0.024), hsa-miR-142-3p (p=0.038), hsa-miR-146a-
5p (p=0.043) and hsa-miR-363-3p (p=0.023). Across all subsites, down-regulation of hsa-miR-29c-
3p (p=0.045) and hsa-miR-150-5p (p=0.019), and up-regulation of hsa-miR-142-3p (p=0.016) were 
associated with increasing nodal stage at diagnosis. There was no difference with the inclusion of 
HPV status across all subsites.  
 
With increasing M-stage at diagnosis, in the oropharynx, hsa-miR-155-5p was up-regulated 
(p=0.018). Across all subsites, increasing M-stage at diagnosis correlated with up-regulation of hsa-
miR-15b-5p (p=0.026) and hsa-miR-150-5p (p=0.025). There was no difference when analysed for 
HPV tumour status in the oropharynx or across all subsites.   
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3.3.7 Survival 
A statistically significant difference in survival was only observed between HPV-positive and 
negative tumours in the oropharynx. The Kaplan-Meier curve for oropharyngeal tumours and 
corresponding statistics are given in Figure 3.2 and Table 3.6.  
 
Figure 3.2: The Kaplan-Meier survival curve demonstrates a significant difference in disease-specific 
survival in HPV-positive oropharyngeal tumours (green) compared with HPV-negative tumours 
(blue). 
 
Table 3.6: Overall comparison statistics corresponding to the Kaplan-Meier survival curve for 
oropharyngeal tumours 
 Chi-Square df Sig 
Log Rang (Mantel-
Cox) 
8.078 1 0.004 
Breslow 
(Generalized 
Wilcoxon) 
10.106 1 0.001 
Tarone-Ware 9.332 1 0.002 
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Disease-free survival (DFS) 
Across all subsites combined, miR-20b was significantly associated with DFS (p=0.002) when HPV 
status, stage at diagnosis and smoking status were taken into account. No miRNAs were significantly 
associated with DFS when HPV status was not considered. In the oropharynx, no miRNAs were 
significantly associated with DFS when HPV status was taken into account, along with stage at 
diagnosis and smoking status. However, when HPV status was not considered, hsa-miR-20b-5p was 
significantly associated with DFS (p=0.008). When evaluating tumours of the oral cavity, along with 
HPV status and smoking status, hsa-miR-20b-5p (p=0.021) and hsa-miR-363-3p (p=0.018) were 
significantly associated with DFS. In HPV-negative tumours of the oral cavity, hsa-miR-363-3p was 
once again significantly associated with DFS (p=0.015).  
 
Recurrence-free survival (RFS) 
Across all subsites combined, three miRNAs were significantly associated with RFS when HPV 
status and smoking status were taken into account. These were: hsa-miR-29a-3p (p<0.001), hsa-miR-
30e-5p (p=0.037) and hsa-miR-342-3p (p=0.019). No miRNAs were significant when HPV status 
was not considered. In oropharyngeal tumours, hsa-miR-16-2-3p was significantly associated with 
RFS (p=0.01) when HPV status was considered, however, retained its significance when HPV status 
was removed from the analysis (p=0.011). Two other miRNAs were also associated with RFS when 
HPV status was not considered: hsa-miR-29a-3p (p=0.004), and hsa-miR-155-5p (p=0.001). No 
miRNAs were significantly associated with RFS in the oral cavity with and without consideration of 
HPV tumour status.  
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CHAPTER FOUR: Predicted target functionality  
4.1 hsa-miR-15a-5p and hsa-miR-15b-5p 
The top twenty target genes identified across all four target prediction programs are given, along with 
their corresponding scores from each program, in Table 4.1. TargetScan interrogation revealed 968 
putative targets, with 1071 conserved and 324 poorly conserved sites. DIANA microT-CDS 
investigation revealed 1611 potential target genes, and the miRANDA-mirSVR database found 8785 
potential target genes.  
 
DAVID Analysis of these genes identified two distinct functional clusters: Group 1 contained CBX4, 
PURA, MYBL1, MYB, MED26 and PLAG1 (enrichment score 1.36), and Group 1 contained 
PLSCR4, PCMT1, SEMA6D, GPR63 and UNC80 (enrichment score 0.38). Investigation of the 
DAVID functional classification database using miRSystem identified genes (number 1198), 
identified five enriched pathways (Refer to Table 4.2) including those associated with carcinogenesis 
such as regulation of transcription and cell proliferation. Of these, TLK1 was identified in cluster 1, 
and PLAG1 was identified in cluster 3. GO analysis revealed over-representation of molecular 
functions such as ubiquitination, protein kinase activity and transcription regulation (p<0.0001), and 
of biological functions including apoptosis, ubiquitination, transcription regulation, cell signaling and 
proliferation (p<0.0001).  
 
Table 4.1: Top twenty predicted targets for hsa-miR-15a-5p and hsa-miR-15b-5p 
Target gene Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
Validated [83] 
USP15 Uniquitin specific 
peptidase 15 
0.950 0.977 -2.570 Yes 
UNC80 Unc-80 homolog, 
NALCN activator 
0.540 0.982 -2.830 No 
MYB MYB proto-oncogene 0.980 0.998 -2.230 Yes 
TLK1 Tousled like kinase 1 0.980 1.000 -2.210 Yes 
ARIH1 Ariadne RBR E3 
ubiquitin protein ligase 1 
0.860 0.765 -2.430 Yes 
MYBL1 MYB proto-oncogene 
like 1 
0.980 0.987 -2.070 Yes 
CCNE1 Cyclin E1 0.970 1.000 -2.020 Yes 
DNAJB4 DnaJ head shock protein 
(Hsp40) member B4 
0.950 0.981 -2.040 No 
ANO3 Anoctamin 3 0.790 0.959 -2.130 No 
WEE1 WEE1 G2 checkpoint 
kinase 
0.980 1.000 -1.850 Yes 
C1QL3 Complement C1q like 3 0.760 0.814 -2.250 No 
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Table 4.2: Functionally enriched target gene groups of hsa-miR-15a-5p and hsa-miR-15b-5p 
identified by gene functional classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Protein phosphorylation, ATP binding, 
Nucleotide binding, Intracellular signal 
transduction 
9.53 18 
Cell membrane transport and signaling, 
Cell proliferation 
5.64 13 
Metal ion binding, DNA binding, 
Transcription regulation 
4.56 32 
Cadherin, cell adhesion, cell signaling, 
calcium binding 
3.80 15 
Kelch, Actin binding, Cytoskeleton 2.42 5 
 
 
IPA network analysis identified 25 gene networks involved in critical cellular pathways (Refer to 
Table 4.3). The top up-stream regulators identified were miR-16 (p=5.71E-16), miR-15 (p=4.24E-7), 
miR-34 (p=9.22E-7), TP53 (5.25E-6) and ESR1 (1.91E-5). Other regulators included MYC, Histone 
H2, E2F1, WNT3A, FGF2 and IGF1. The top canonical pathways targeted include insulin receptor 
signaling, the PTEN and STAT3 pathways, axonal guidance and molecular mechanisms of cancer 
pathway. Comparison of the top 20 targets identified in this study with those involved in the top 10 
IPA networks, revealed significant cross-over. ANO3 was found to be a member of Group 1; MYB, 
MYBL1, DNAJB4 and WEE1 were members of Group 2; CCNE1 is in Group 3; and CBX4 was 
contained in Group 4. Group 8 contained PPP1R11 and SHOC2; while Group 9 contained COL12A1.  
 
 
COL12A1 Collagen type XII alpha 
1 chain 
0.900 0.837 -2.080 No 
PLSCR4 Phospholipid scramblase 
4 
0.460 0.932 -2.420 Yes 
SHOC2 Leucine rich repeat 
scaffold protein 
0.940 0.935 -1.900 Yes 
C2orf42 Chromosome 2 open 
reading frame 42 
0.770 0.893 -2.070 Yes 
PLAG1 PLAG1 zinc finger 0.980 1.000 -1.740 Yes 
PPP1R11 Protein phosphatase 1 
regulatory inhibitor 
subunit 11 
0.820 0.986 -1.910 Yes 
SLC9A6 Solute carrier family 9 
member A6 
0.750 0.884 -2.060 Yes 
CBX4 Chromobox 4 0.840 0.991 -1.860 Yes 
GPR63 G-protein coupled 
receptor 63 
0.990 0.928 -1.770 No 
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Table 4.3: Top ten networks for hsa-miR-15 target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Post-translational 
modification, cell-to-cell 
signaling and interaction, 
hair and skin 
development and 
function 
33 Cellular development, 
cellular growth and 
proliferation, 
haematological system 
development and 
function 
30 
Gene expression, cancer, 
gastrointestinal disease 
32 Carbohydrate 
metabolism, cellular 
function and 
maintenance, molecular 
transport 
29 
Haematological system 
development and 
function, 
haematopoiesis, 
lymphoid tissue structure 
and development 
32 Lipid metabolism, 
molecular transport, 
small molecule 
biochemistry 
27 
Cancer, haematological 
disease, immunological 
disease 
31 Cancer, organismal 
injury and abnormalities, 
respiratory disease 
27 
Embryonic development, 
organismal development, 
cellular development 
30 Immunological disease, 
gastrointestinal disease, 
hepatic system disease 
26 
 
4.2 hsa-miR-16 
The top twenty target genes identified across all four target prediction programs are given, along with 
their corresponding scores from each program, in Table 4.4. Interrogation of TargetScan revealed 
4497 possible target mRNA transcripts, containing a total of 6699 possible binding sites. The DIANA 
microT-CDS database identified 840 possible target genes, while miRANDA-mirSVR found 7754 
potential target genes.  
 
Analysis (DAVID) of these genes identified two clusters of functionally related genes: Group 1 
contained MYEF2, CPEB2, PURA and CPEB3 (enrichment score 1.61), and Group 2 contained 
MIER3, ZNF624 and MYEF2 (enrichment score 1.49). DAVID analysis of all putative target genes 
(1147) identified across at least three databases by MiRSystem interrogation revealed over-
representation of molecular functions such as protein kinase activity, ATP binding, and protein and 
ion transport (p<0.0001), as well as biological functions such as ubiquitination, intra-cellular 
signaling, cell differentiation and cytoskeleton functions (p<0.0001). Functional gene classification 
identified four enriched pathways (Refer to Table 4.5). Of these clusters, TLK1 was identified in 
cluster 1, and PLAG1 was identified in cluster 3.  
 
 
 
38 | 97 
Table 4.4: Top twenty predicted targets for hsa-miR-16 
Target gene Full Gene Name TargetScan 
Total context 
++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
TLK1 Tousled like kinase 1 -0.060 0.977 -2.220 Yes 
NGLY1 N-glycanase 1 -0.490 0.729 -1.560 No 
PURA Prune rich element binding 
protein A 
-0.280 0.744 -1.740 Yes 
PLAG1 PLAG1 zinc finger -0.170 0.744 -1.710 Yes 
NAA30 N(alpha)-acetyltransferase 
30 
-0.350 0.978 -1.260 No 
ACADM Acyl-CoA dehydrogenase, 
C-4 to C-12 straight chain 
-0.520 0.825 -1.240 No 
MIER3 MIER family member 3 -0.230 0.802 -1.450 No 
TMEM7B Transmembrane protein 7B -0.080 0.915 -1.460 No 
CDK17 Cyclin dependent kinase 17 -0.130 0.956 -1.350 Yes 
MYEF2 Myelin expression factor 2 -0.100 0.771 -1.540 No 
CPEB3 Cytoplasmic 
polyadenylation element 
binding protein 3 
-0.040 0.956 -1.410 Yes 
CUL2 Cullin 2 -0.310 0.912 -1.160 Yes 
ANKIB1 Ankyrin repeat and IBR 
domain containing 1 
-0.050 0.719 -1.610 No 
ECAFB1  -0.500 0.768 -1.110 No 
PAFAH1B1 Platelet activating factor 
acetylhydrolase 1b 
regulatory subunit 1 
-0.140 0.980 -1.250 Yes 
CPEB2 Cytoplasmic 
polyadenylation element 
binding protein 2 
-0.150 0.988 -1.210 Yes 
CYP26B1 Cytochrome P450 family 26 
subfamily B member 1 
-0.210 0.933 -1.200 Yes 
B2M Beta-2-microglobulin -0.500 0.706 -1.110 Yes 
NOVA1 NOVA alternative splicing 
regulator 1 
-0.060 0.978 -1.200 No 
GALNT1 Polypeptide N-acetyl 
galactosaminyltransferase 1 
-0.240 0.895 -1.090 Yes 
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Table 4.5: Functionally enriched target gene groups of hsa-miR-16 identified by gene functional 
classification in DAVID  
Functional classification group 
 
Enrichment score Number of target genes 
Protein kinase activity, ATP binding, 
phosphorylation, cell cycle 
9.87 18 
Cell membrane structure and function 5.97 16 
Metal ion binding, nucleotide binding, 
transcription regulation 
4.52 30 
Cadherin, cell adhesion, cell signaling, 
calcium binding 
3.87 15 
 
IPA pathway analysis revealed 25 target gene networks. The top 10 are listed in Table 4.6. The top 
up-stream regulators of these pathways were identified as miR-16 (p=3.39E-16), miR-15 (p=3.23E-
7), ESR1 (3.19E-6), miR-34 (p=6.47E-6) and TP53 (p=6.87E-6). Other statistically significant 
(p<0.0001) upstream regulators include MYC, E2F1, VEGFA, IGF1 and WNT3A. The top canonical 
pathways targeted by miR-16 are PTEN, STAT2, Insulin and B-cell receptor signaling and molecular 
mechanisms of cancer pathway. Within these top 10 gene networks, several of the top 20 target genes 
identified in this study were found, including MYEF2 in Group 1; CUL2 in Group 2; and PLAG1 
and CPEB2 in Group 7.  
 
Table 4.6: Top ten networks for hsa-miR-16 target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Gene expression, lipid 
metabolism, molecular 
transport 
33 Cellular development, 
cellular growth and 
proliferation, embryonic 
development 
29 
Post-translational 
modification, cell death 
and survival, gene 
expression 
32 Cancer, organismal 
injury and abnormalities, 
respiratory disease 
28 
Gene expression, DNA 
replication, 
recombination and repair, 
cancer 
32 Endocrine system 
disorders, metabolic 
disease, carbohydrate 
metabolism 
27 
Cellular compromise, 
cell morphology, 
molecular transport 
31 Embryonic development, 
organ development, 
organismal development 
25 
Cancer, organismal 
injury and abnormalities, 
reproductive system 
disease 
30 Nervous system 
development and 
function, organ 
morphology, organismal 
development 
25 
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4.3 hsa-miR-20b-5p 
hsa-miR-20b-5p belongs to the miR-17 family, which also includes miR-20a, miR-93 and miR-
106a/b. This study has identified up-regulation of hsa-miR-20b-5p in HPV-related tumours. The top 
twenty predicted targets for hsa-miR-20b-5p are listed in Table 4.7. TargetScan identified 1384 
possible target gene transcripts, with 1649 conserved and 898 poorly conserved possible binding sites. 
DIANA microT-CDS found 480 possible targets, and miRANDA-mirSVR identified 9122 potential 
target genes.  
 
Table 4.7: Top twenty predicted targets for hsa-miR-20b-5p 
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Target 
Gene 
Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA  
miTG 
miRANDA 
mirSVR  
Experimentally 
validated [83] 
DYNC1LI2 Dynein cytoplasmic 1 
light intermediate chain 2 
0.980 0.986 -2.930 Yes 
ZNFX1 Zinc finger NFX1-type 
containing 1 
>0.990 1.000 -2.770 Yes 
KPNA3 Karyopherin subunit 
alpha 3 
0.810 0.918 -2.510 No 
C14orf28 Chromosome 14 open 
reading frame 28 
0.740 0.952 -2.390 Yes 
SCN1A Sodium voltage-gated 
channel alpha subunit 1  
>0.990 0.976 -2.300 No 
PKD2 Polycystin 2, transient 
receptor potential cation 
channel (polycystic 
kidney disease),  
>0.990 0.999 -2.250 No 
LHX8 LIM homeobox 8 (neural 
tube development) 
0.740 0.969 -2.290 No 
STAT3 Signal transducer and 
activator of transcription 
3 
0.930 0.920 -2.100 Yes 
PFN2 Profilin 2  0.920 0.995 -1.990 No 
TXNIP Thioredoxin interacting 
protein  
0.970 0.993 -1.910 Yes 
ZFYVE26 Zinc finger FYVE-type 
containing 26 
>0.990 0.925 -1.890 Yes 
PCDHA4  Protocadherin alpha 4  0.760 0.911 -2.110 No 
SERP1 Stress associated 
endoplasmic reticulum 
protein 1  
0.960 0.961 -1.840 No 
PCDHA6  Protocadherin alpha 6 0.760 0.910 -1.970 No 
PCDHA2  Protocadherin alpha 2  0.760 0.910 -1.970 No 
PCDHA3  Protocadherin alpha 3 0.760 0.910 -1.970 No 
NR4A3 Nuclear receptor 
subfamily 4 group A 
member 3  
0.930 0.986 -1.580 No 
FCHO2 FCH domain only 2 0.920 0.996 -1.500 Yes 
RAB11FIP5 RAB11 family interacting 
protein 5  
0.960 0.998 -1.330 No 
PCNP PEST proteolytic signal 
containing nuclear protein  
0.740 0.759 -1.740 No 
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DAVID analysis of these genes identified one cluster of genes containing PCDHA6, PRRG1 and 
PCDHA4 (enrichment score 0.85). To further assess the biological relevance of predicted targets for 
miR-20b, gene ontologies (GO) were explored for all putative target genes identified across at least 
three distinct databases, using miRSystem. miRSystem interrogation revealed 1121 target genes 
identified across at least three databases. These functional gene group classifications are listed in 
Table 4.8. Three target genes identified in the top twenty target genes were contained in Group 4: 
PCDHA2, 3, 4, and 6. GO enrichment analysis identified over-representation of biological processes 
such as regulation of cell cycle progression, cell proliferation and apoptosis; as well as cell migration, 
adhesion and signaling (p < 0.0001). Molecular functions were also over-represented, related to 
protein and ion binding; cytoskeleton activity; and transcription factor activation (p < 0.0001).  
 
Table 4.8: Enriched hsa-miR-20b-5p target gene groups identified by gene functional classification 
in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Protein kinase activity, phosphorylation, 
intra-cellular signalling 
10 22 
Protein kinase activity, intra-cellular 
signaling, nucleotide binding, protein 
phosphorylation 
6.82 5 
Transcription regulation, DNA binding 6.44 50 
Cadherin, cell adhesion, calcium binding 4.77 16 
Ubiquitin protein activity, cytoskeleton 
organization, Kelch 
3.29 7 
GTP-binding, GTPase activity, intra-
cellular signalling 
2.66 6 
Inter-cellular signaling, cell secretion 2.3 6 
 
Network analysis of the 1121 genes identified by miRSystem identified 25 gene networks involved 
in critical cellular pathways, and the top ten are detailed in Table 4.9. The top regulators included 
SP3 (p=1.68E-7), Histone H4 (p=1.28E-6), NR3C1 (p=1.86E-6), TFAP2A (p=3.03E-6) and TP63 
(6.33E-6). However, up-stream regulators also included E2F1 (p=1.82E-4), TP53 (p=8.33E-4), 
CDKN2A (p=3.25E-3) and EGF1 (p=1.98E-3). The top canonical pathways targeted include 
molecular mechanisms of cancer pathways, NGF signaling, HGF signaling and cell cycle regulation 
by the BTG family of proteins.  Of the genes involved in the top gene networks identified in IPA, 
several were also found in the top 20 putative targets identified in this study. These included PCDHA4 
in Group 5; TXNIP in Group 6; PFN2 and NR4A3 in Group 7; and STAT3 in Group 8.  
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Table 4.9: Top ten networks for hsa-miR-20b-5p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Cardiovascular disease, 
organismal injury & 
abnormalities, 
reproductive system 
disease 
34 Cellular growth & 
proliferation, tissue 
development, cancer 
31 
Cellular growth and 
proliferation, gene 
expression, survival 
33 Cellular development, 
cellular growth & 
proliferation, cellular 
movement 
31 
Gene expression, cellular 
movement, survival 
31 Cell death & survival, 
cellular movement, gene 
expression 
27 
Cardiovascular system 
development & function, 
connective tissue 
disorders 
31 Cell cycle, connective 
tissue development & 
function, cellular 
development 
25 
Cancer, hematological 
disease, organismal 
injury & abnormalities 
31 Gene expression, protein 
synthesis, infectious 
diseases 
20 
 
4.4 hsa-miR-29a-3p 
The top twenty predicted gene targets for hsa-miR-29a-3p are listed in Table 4.10. TargetScan 
identified 1256 possible gene targets, with a total of 1455 conserved and 319 poorly conserved sites. 
DIANA microT-CDS identified 991 potential target genes, and miRANDA-mirSVR found 6777 
potential targets. DAVID analysis revealed one functional cluster of genes: COL4A1, PXDN, 
COL3A1, ELN, COL5A2, COL5A1, COL1A2 and PDGFC (enrichment score 4.76).  
 
miRSystem identified 875 potential target genes across at least three databases. GO interrogation of 
this list revealed over-representation of biological functions such as cell adhesion, extracellular 
matrix formation and function, and cytoskeleton organization and function (p<0.0001), and of 
molecular functions including protein binding, ubiquitination, transcription factor activity and 
calcium binding (p<0.0001). Seven clusters of genes were functionally enriched, and these are listed 
in Table 4.11. Five genes from the top twenty targets identified in this study were found in cluster 2: 
COL3A1, COL11A1, COL1A2, COL5A1, and COL5A2.  
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Table 4.10: Top twenty predicted targets for hsa-miR-29a-3p 
Target 
Gene 
Full Gene Name TargetScan 
score 
Aggregate PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally validated 
[83] 
COL3A1 Collagen type III alpha 1 
chain 
>0.990 1.000 -2.650 Yes 
TDG Thymine DNA glycosylase 0.900 0.967 -2.410 Yes 
PDGFC Platelet derived growth 
factor C 
0.920 0.971 -2.360 No 
HBP1 HMG-box transcription 
factor 1 
0.950 1.000 -2.330 Yes 
COL11A1 Collagen type XI alpha 1 
chain 
0.970 0.986 -2.270 No 
ATAD2B ATPase family, AAA 
domain containing 2B 
>0.990 1.000 -2.220 No 
TET2 Tet methylcytosine 
dioxygenase 2 
>0.990 0.994 -2.030 Yes 
ELN Elastin >0.990 1.000 -1.920 No 
COL1A2 Collagen type I alpha 2 
chain 
0.990 0.990 -1.880 No 
REV3L REV2 like, DNA directed 
polymerase zeta catalytic 
subunit 
0.990 0.901 -1.950 No 
JARID2 Jumonji and AT-rich 
interaction domain 
containing 2 
0.850 0.724 -2.250 No 
HMCN1 Hemicentin 1 0.750 0.994 -2.060 No 
COL5A1 Collagen type V alpha 1 
chain 
>0.990 0.986 -1.760 No 
PTEN Phosphatase and tensin 
homolog 
>0.990 0.983 -1.740 Yes 
MAPRE1 Microtubule associated 
protein RP/EB family 
member 1 
0.840 0.948 -1.920 No 
TET1 Tet methylcytosine 
dioxygenase 1 
>0.990 0.991 -1.710 Yes 
OTUD4 OUT deubiquitinase 4 0.880 0.980 -1.630 Yes 
CCNJ Cyclin J 0.740 0.998 -1.750 No 
COL5A2 Collagen type V alpha 2 
chain 
>0.990 0.992 -1.450 Yes 
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ARRDC3 Arrestin domain containing 
3 
0.950 0.941 -1.450 No 
 
 
Table 4.11: Functionally enriched target gene groups of hsa-miR-29a-3p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Extracellular matrix, basement 
membrane and collagen structure and 
function, angiogenesis, cell 
proliferation, cell differentiation 
6.25 6 
Extracellular matrix formation and 
function, calcium metabolism, collagen 
6.20 8 
Cadherin, calcium regulation, cell 
adhesion 
5.27 16 
Protein kinase activity, phosphorylation, 
ATP & nucleotide binding 
3.20 12 
Transcription, metal binding, nucleic 
acid binding  
3.17 27 
Peptidase, metal ion binding, cell 
membrane function 
3.06 9 
Translation, chromosome arrangement, 
protein binding 
2.97 6 
 
IPA analysis identified 25 gene networks, and the top 10 are listed in Table 4.12. The top up-stream 
regulators are miR-29 (p=2.52E-9), TGFB1 (p=1.19E-9), ERF (p=1.15E-7) and NR3C1 (p=2.27E-
7). Other significant regulators (p<0.0001) are PGF, ERBB2, ESR1, IFN-B, GH, TNF, TP63, and 
PI3K. Top canonical pathways involved included axonal guidance signaling, PAK signaling and 
glioma signaling. Several of the top twenty predicted target genes for miR-29a were identified in the 
leading gene networks identified in IPA. These include: COL5A1 and COL5A2 in Group 1; PDGFC 
in Group 5; COL3A1 and ELN in Group 6; HBP1 in Group 8; and PTEN in Group 10.  
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Table 4.12: Top ten networks for hsa-miR-29a-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Connective tissue 
disorders, organismal 
injury and abnormalities, 
cancer 
32 Cellular assembly and 
orgnisation, tissue 
development, embryonic 
development 
27 
Gene expression, 
cardiovascular disease, 
haematological disease 
31 Post-translational 
modification, cellular 
movement, cellular 
development 
27 
Cancer, organismal 
injury and abnormalities, 
reproductive system 
disease 
31 Cell-to-cell signaling and 
interaction, cellular 
assembly and 
organization, tissue 
development 
27 
Haematological disease, 
immunological disease, 
antimicrobial response 
28 Cell morphology, cell-to-
cell signaling and 
interaction, nervous 
system development and 
function 
26 
Cardiovascular disease, 
tissue morphology, DNA 
replication, 
recombination and repair 
28 Cancer, organismal 
injury and abnormalities, 
tissue morphology 
25 
 
4.5 hsa-miR-29c-3p 
The top twenty predicted gene targets for hsa-miR-29c-3p are given in Table 4.13. miRANDA-
mirSVR identified a possible 6856 gene targets, while DIANA microT-CDS identified 23 possible 
targets. TargetScan identified 409 possible transcripts, with a total of 413 possible binding sites. 
DAVID analysis identified one functional genetic cluster in these genes: ZNF346, YY1 and ZNF468 
(enrichment score 0.59).  
 
MiRSystem interrogation revealed 875 putative target genes identified across three databases. GO 
analysis revealed over-representation of biological functions including extracellular matrix 
organization, cell adhesion, and regulation of cell proliferation (p<0.0001), as well as over-
representation of molecular functions such as protein binding, ubiquitination, growth factor activity 
and calcium binding (p<0.0001). Functional gene clustering of these identified seven enriched 
functional clusters (Refer to Table 4.14). None of the top twenty target genes identified in this study 
were identified in these clusters.  
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Table 4.13: Top twenty predicted targets for hsa-miR-29c-3p 
Target 
gene 
Full Gene Name TargetScan  
Total context 
++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
PTBP2 Polypyrimidine tract binding 
protein 2 
-0.350 0.492 -2.010 No 
ELN Elastin -0.370 0.454 -1.920 No 
MYCN v-myc avian 
myelocytomatosis viral 
oncogene neuroblastoma 
derived homolog 
-0.370 0.751 -1.080 Yes 
DNMT3A DNA methyltransferase 3 
alpha 
-0.290 0.481 -1.220 Yes 
BZW1 Basic leucine zipper and W2 
domains 1 
-0.180 0.505 -1.050 No 
CAPRIN1 Cell cycle associated protein 
1 
-0.230 0.435 -1.070 No 
LIMS1 LIM zinc finger domain 
containing 1 
-0.230 0.522 -0.940 Yes 
YY1 YY1 transcription factor -0.210 0.431 -1.010 No 
ATP6V1A ATPase H+ transporting V1 
subunit A 
-0.480 0.596 -0.560 No 
DOLPP1 Dolichyldiphosphatase 1 -0.250 0.435 -0.94 No 
CLEC7A C-type lectin domain family 
7 member A 
-0.240 0.410 -0.960 No 
COL22A1 Collagen type XXII alpha 1 
chain 
-0.220 0.529 -0.840 No 
MYO1D Myosin 1D -0.200 0.454 -0.920 No 
CRISPLD2 Cysteine rich secretory 
protein LCCL domain 
containing 2 
-0.230 0.408 -0.880 No 
CCNYL1 Cyclin Y like 1 -0.240 0.407 -0.860 No 
KCTD5 Potassium chanel 
tetramerization domain 
containing 5 
-0.290 0.412 -0.750 No 
ZNF468 Zinc finger protein 468 -0.180 0.375 -0.750 No 
ZNF346 Zinc finger protein 346 -0.290 0.446 -0.560 No 
FMN1 Formin 1 -0.200 0.443 -0.580 No 
XKR4 XK related 4 -0.120 0.401 -0.700 No 
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Table 4.14: Functionally enriched target gene groups of hsa-miR-29c-3p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Collagen, cell adhesion 6.54 6 
Collagen, extracellular matrix 
organization, cell signalling 
6.37 8 
Cadherin, calcium ion binding, cell 
adhesion 
5.31 16 
Peptidase activity, metal ion binding,  3.19 9 
Protein kinase activity, phosphorylation, 
ATP binding 
3.13 12 
Zinc finger, metal ion binding, 
transcription regulation, nucleic acid 
binding 
3.08 27 
WD40, phosphorylation, translation 
initiation 
2.92 6 
 
IPA analysis found 25 target gene networks, the top 10 of which are listed in Table 4.15. The top 
canonical pathways targeted are axonal guidance signaling, PAK and glioma signaling pathways. Top 
regulators of these networks include miR-29 (p=2.54E-9), TGFB1 (p=3.47E-10), Estrogen receptor 
(p=8.85E-8) and ERK (p=1.17E-7). Other regulators (p<0.0001) include IFN-B, TFAP2A, NR3C1, 
SPDEF, TNF and TP53. Several of the top 20 predicted targets identified in this study were found to 
be involved in the top networks identified in IPA. These include: MYCN and YY1 in Group 1; 
ZNF346 in Group 3; DNMT3A in Group 4; and ELN in Group 10.  
 
Table 4.15: Top ten networks for hsa-miR-29c-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Gene expression, 
organismal survival, 
embryonic development 
32 Cancer, organismal 
injury and abnormalities, 
cellular assembly and 
organization 
27 
Cell death and survival, 
haematological disease, 
immunological disease 
30 Cellular assembly and 
organization, tissue 
development, cancer 
25 
Cellular growth and 
proliferation, connective 
tissue development and 
function, tissue 
development 
30 Port-translational 
modification, protein 
degradation, protein 
synthesis 
25 
Cardiovascular disease, 
tissue morphology, DNA 
replication, 
recombination and repair 
29 Organismal 
development, cell death 
and survival, 
gastrointestinal disease 
24 
Cell-to-cell signaling and 
interaction, nervous 
system development and 
function, cardiovascular 
system development and 
function 
28 Cell death and survival, 
cellular development, 
cellular growth and 
proliferation 
24 
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4.6 hsa-miR-30e-5p 
The top twenty predicted targets for hsa-miR-30e-5p are given in Table 4.16. TargetScan found a 
total of 1566 transcripts, with 1848 conserved and 565 poorly conserved sites. DIANA microT-CDS 
identified 1787 possible gene targets, and miRANDA-miR-SVR found 6323 potential target genes. 
DAVID analysis of the genes did not identify any functional clusters.  
 
GO analysis revealed over-representation in molecular functions such as protein binding, 
ubiquitination, chromatin binding and transcription factor activity (p<0.0001), as well as biological 
functions such as transcription regulation, signal transduction, intracellular transport, and apoptosis 
(p<0.0001). Investigation of miRSystem targets for miR-30e found 1150 target genes across at least 
three databases. Functional classification of these genes identified 8 enriched clusters (Refer to Table 
4.17). Of the top target genes identified in this study, RARB was identified in cluster 1, WDR7 in 
cluster 3 and SCN2A in cluster 7. 
 
Table 4.16: Top twenty predicted targets for hsa-miR-30e-5p 
Target Gene Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
CELSR3 Cadherin EGF LAF seven-
pass G-type receptor 3 
>0.990 1.000 -4.050 Yes 
RAP1B RAP1B, member of RAS 
oncogene family 
0.810 0.993 -3.710 Yes 
RFX6 Regulatory factor X6 0.990 1.000 -3.480 No 
XPO1 Exportin 1 0.940 0.991 -3.200 Yes 
TNRC6A Trinucleotide repeat 
containing 6A 
>0.990 1.000 -3.110 Yes 
ANKRA2 Ankyrin repeat family A 
member 2 
0.650 0.991 -3.200 Yes 
MEX3B Mex-3 RNA binding family 
member B 
0.960 1.000 -2.840 No 
RAD23B RAD23 homolog B 0.960 0.962 -2.770 Yes 
SCN2A Sodium voltage-gated 
channel subunit 2 
0.950 1.000 -2.700 No 
B3GNT5 UDP-GlcNAc:betaGal beta-
1,3-N-
acetylglucosaminyltransferase 
5 
0.990 0.997 -2.630 No 
50 | 97 
RARB Retinoic acid receptor beta 0.900 0.950 -2.750 No 
LHX8 LIM homeobox 8 0.980 1.000 -2.590 No 
WDR7 WD repeat domain 7 0.980 0.942 -2.640 No 
UBE2V2 Ubiquitin conjugating 
enzyme E2 V2 
0.960 0.982 -2.610 No 
PDE7A Phosphodiesterase 7A >0.990 1.000 -2.520 No 
PTPN13 Protein tyrosine phosphatase, 
non-receptor type 13 
0.830 0.983 -2.690 No 
FOXG1 Forkhead box G1 0.930 0.986 -2.560 Yes 
CBLB Cbl proto-oncogene B 0.870 0.972 -2.540 No 
PAPD4 Poly(A) RNA polymerase D4 -0.970 0.997 -2.360 No 
RFX7 Regulatory factor X7 0.880 0.993 -2.450 No 
 
Table 4.17: Functionally enriched target gene groups of hsa-miR-30e-5p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
DNA binding, steroid hormone receptor 
function, transcription regulation 
7.56 9 
Zinc finger, metal ion binding, 
nucleotide binding, transcription 
regulation 
6.10 38 
Protein kinase activity, nucleotide 
binding, ATP binding, intracellular 
signal transduction 
5.26 15 
Ubiquitination, ATP binding 4.15 5 
WD40, cytoskeleton structure and 
function, calcium binding 
3.97 6 
GTP binding, methylation, intracellular 
vesicle function, endocytosis 
3.66 8 
Sodium channel function, Action 
potential, cell membrane function 
3.11 5 
Immunoglobulin, cell adhesion, cell 
membrane structure and function 
2.14 6 
 
25 target gene networks were identified on IPA analysis. The top 10 are listed in Table 4.18. The top 
canonical pathways involved included axonal guidance signaling, Reelin signaling in neurons, 
cardiac hypertrophy signaling, integrin signaling and B-cell receptor signaling. The predominant up-
stream regulators included miR-34 (p=6.39E-7), estrogen receptors (p=5.03E-6), FSH (p=6.93E-6), 
miR-339 (p=7.96E-6) and miR-8 (p=9.08E-6). Others included TNF, CCND1, MAPK1, and E2F1 
(p<0.0001). Within these top 10 networks, several genes identified in Table 4.16 were identified, 
including FOXG1 in Group 2; PTPN13 in Group 4; RARB in Group 5; RAD23B in Group 6; and 
RAP1B in Group 9.  
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Table 4.18: Top ten networks for hsa-miR-30e-5p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Infectious diseases, cell 
death and survival, 
embryonic development 
32 Gene expression, 
respiratory disease, 
cancer 
30 
Gene expression, 
developmental disorder, 
gastrointestinal disease 
31 Cell morphology, organ 
morphology, skeletal and 
muscular disorders 
30 
Amino acid metabolism, 
small molecule 
biochemistry, connective 
tissue development and 
function 
30 Gene expression, cell 
death and survival, 
embryonic development 
29 
Cellular assembly and 
organization, cellular 
function and 
maintenance, 
cardiovascular disease 
30 Cellular growth and 
proliferation, nervous 
system development and 
function, tissue 
morphology 
28 
Cellular growth and 
proliferation, tissue 
development, 
developmental disorder 
30 Cardiac arrhythmia, 
cardiovascular disease, 
hereditary disorder 
28 
 
 
4.7 hsa-miR-142-3p 
The top twenty potential target genes for hsa-miR-142-3p are listed in Table 4.19. TargetScan 
identified 599 possible target gene transcripts, with 662 conserved and 216 poorly conserved binding 
sites. miRANDA-mirSVR identified 4334 possible targets and DIANA microT-CDS identified 517 
possible target genes. DAVID analysis identified one functional genetic cluster, which included 
SLC35F5, TMEM200B, DIRC2, SLC38A4 and STX12 (enrichment factor 0.34).  
 
GO analysis revealed over-representation of molecular functions such as protein, chromatin, metal 
ion and calmodulin binding, GTPase activity, transcription factor activity and cadherin binding 
(p<0.0001). Biological functions including regulation of transcription and gene expression, 
endocytosis, intracellular protein transportation, and regulation of apoptosis were also over-
represented (p<0.0001). MiRSystem identified 336 target genes across at least three databases. 
Functional gene clustering of these target genes identified one functional gene cluster (Refer to Table 
4.20). No genes identified in the top 20 putative targets were identified in this cluster.  
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Table 4.19: Top twenty predicted targets for hsa-miR-142-3p 
Target gene Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
TMEM200B Transmembrane protein 200B 0.780 0.804 -2.770 No 
ARNTL Aryl hydrocarbon receptor 
nuclear translocator like 
0.780 0.999 -2.520 Yes 
USP6NL USP6 N-terminal like 0.960 0.989 -2.190 Yes 
WASL Wiskott-Aldrich syndrome like 0.840 0.999 -2.240 Yes 
C20orf194 Chromosome 20 open reading 
frame 194 
0.940 0.986 -2.130 No 
FNDC3A Fibronectin type III domain 
containing 3A 
0.720 0.924 -2.140 Yes 
RHOBTB3 Rho related BTB domain 
containing 3 
0.770 0.704 -2.200 No 
ASH1L ASH1 like histone lysine 
methyltransferase 
0.800 0.987 -1.870 No 
BOD1 Biorientation of chromosomes 
in cell division 1 
0.980 0.993 -1.680 Yes 
C9orf72 Chromosome 9 open reading 
frame 72 
0.850 0.997 -1.730 Yes 
HMGA2 High mobility group AT-hook 
2 
0.700 0.717 -2.050 Yes 
ADAMTS3 ADAM metallopeptidase with 
thrombospondin type 1 motif 3 
0.730 0.832 -1.900 No 
STAU1 Staufen double-stranded RNA 
binding protein 1 
<0.100 0.949 -2.350 No 
KDM6A Lysine demethylase 6A 0.760 0.824 -1.760 No 
SLC35F5 Solute carrier family 35 
member F5 
0.910 0.971 -1.440 Yes 
SLC38A4 Solute carrier family 38 
member A4 
0.360 0.845 -2.070 No 
RAB2A RAB2A, member RAS 
oncogene family 
0.870 0.999 -1.340 Yes 
CCNJ Cyclin J 0.730 0.887 -1.590 Yes 
MAP4K3 Mitogen-activated protein 
kinase kinase kinase kinase 3 
0.930 0.865 -1.340 No 
STX12 Syntaxin 12 0.730 0.921 -1.460 No 
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Table 4.20: Enriched hsa-miR-142-3p target gene groups identified by gene functional classification 
in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Zinc finger, metal ion binding, nucleic 
acid binding, transcription regulation 
3.36 13 
 
25 target gene networks were identified with IPA analysis, and the top 10 are listed in Table 4.21. 
The top canonical pathways include clathrin-mediated endocytosis signaling, protein-kinase A 
signaling, epithelial adherens junction signaling, and molecular mechanisms of cancer. The top 
regulators include miR-142 (p=1.51E-5), MLK1 (p=3.79E-5), UPF1 (p=5.26E-5), miR-8 (p=6.74E-
5) and FOXO3 (p=1.27E-4).  Other regulators (p<0.0001) include RAB1B, ELK1, IL-2, FOXO1, 
BTG1, STAT5, AKT3, STAT3, TP53 and MTDH. Within these top 10 networks (Refer to Table 
4.21), several target genes identified in this study were found. These include ASH1L and RAB2A in 
Group 1; HMGA2 in Group 2; ARNTL in Group 3; USP6NL, STAU1 and KDM6A in Group 4; 
WASL in Group 5; FNDC3A, RHOBTB3 and STX12 in Group 6; WASL in Group 7; and BOD1 in 
Group 8.  
 
Table 4.21: Top ten networks for hsa-miR-142-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Cancer, organismal 
injury and abnormalities, 
post-translational 
modification 
27 Cellular development, 
inflammatory disease, 
organismal injury and 
abnormalities 
16 
Cellular growth and 
proliferation, cellular 
development, cell death 
and survival 
25 Cellular function and 
maintenance, 
neurological disease, 
organismal injury and 
abnormalities 
14 
Cellular growth and 
proliferation, cellular 
assembly and 
organization, tissue 
development 
25 Cell death and survival, 
cellular movement, 
cellular growth and 
proliferation 
14 
Neurological disease, 
connective tissue 
disorders, 
haematological disease 
22 Cell morphology, cellular 
assembly and 
organization, cancer 
13 
Cell morphology, cellular 
assembly and 
organization, cellular 
function and 
maintenance 
16 Cell death and survival, 
cell cycle, embryonic 
development 
13 
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4.8 hsa-miR-146a-5p 
The top twenty predicted gene targets for hsa-miR-146a-5p are listed in Table 4.22. DIANA microT-
CDS identified 854 possible targets, and miRANDA-mirSVR found 6798 possible target genes. 
TargetScan found 275 possible target gene transcripts, with a total of 290 conserved and 124 poorly 
conserved possible binding sites. Functional clustering analysis (DAVID) identified two clusters of 
target genes: Group 1 contained RARB, KLF7, MYBL1, HNRNPD and ZBTB2 (enrichment score 
1.2); and Group 2 contained SLC19A3, LFNG, IGSF1 and SLC10A3 (enrichment score 0.14).  
 
Table 4.22: Top twenty predicted targets for hsa-miR-146a-5p 
Target 
Gene 
Full Gene Name TargetScan 
Total 
context ++ 
DIANA  
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
NOVA1 NOVA alternative splicing 
regulator 1 
-0.490 0.892 -2.980 No 
TRAF6 TNF receptor associated factor 6 -1.000 1.000 -2.320 Yes 
IGSF1 Immunoglobulin superfamily 
member 1 
-0.670 1.000 -2.320 No 
IRAK1 Interleukin 1 receptor associated 
kinase 1 
-0.560 1.000 -1.670 Yes 
ZBTB2 Zinc finger and BTB domain 
containing 2 
-0.570 0.998 -1.490 No 
WWC2 WW and C2 domain containing 2 -0.650 0.953 -1.380 No 
ZHDDC13  -0510 0.983 -1.310 No 
HNRNPD Heterogeneous nuclear 
ribonucleoprotein D 
-0.520 0.983 -1.300 No 
CKDN2AIP  -0.580 0.931 -1.240 No 
ZNRF2 Zinc and ring finger 2 -0.520 0.719 -1.440 No 
NUMB NUMB, endocytic adaptor protein -0.380 0.938 -1.340 Yes 
RARB Retinoic acid receptor beta -0.390 0.973 -1.290 No 
EIF4G2 Eukaryotic translation initiation 
factor 4 gamma 2 
-0.350 0.975 -1.320 No 
SLC10A3 Solute carrier family 10 member 3 -0.530 0.985 -1.120 No 
SLC19A3 Solute carrier family 19 member 3 -0.310 0.812 -1.500 No 
STRBP Spermatid perinuclear RNA 
binding protein 
-0.330 0.900 -1.330 No 
KLF7 Kruppel like factor 7 -0.310 0.998 -1.250 No 
MYBL1 MYB proto-oncogene like 1 -0.180 0.968 -1.390 No 
RFTN2 Raftlin family member 2 -0.160 0.749 -1.550 No 
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LFNG LFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
-0.390 0.872 -1.100 No 
 
340 putative target genes were identified across at least three databases using miRSystem. GO 
analysis found that biological functions such as regulation of cell proliferation, DNA transcription, 
cell migration, ubiquitination and control of the cell cycle were over-represented (p<0.0001), as were 
molecular functions such as transcription factor activity, co-receptor binding, protein kinase activity 
and ubiquitin-protein activity (p<0.0001). Gene functional classification identified one enriched 
cluster of genes (Refer to Table 4.23). Of these, KLF7 and ZBTB2 were also identified in our top 
twenty putative target genes for miR-146a.  
 
Table 4.23: Functionally enriched target gene groups of hsa-miR-146a-5p identified by gene 
functional classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Transcription regulation, zinc finger, 
metal ion binding, DNA binding, cell 
division 
3.21 17 
 
Of the 25 target gene networks identified, the top 10 are listed in Table 4.24. Top canonical pathways 
included a-adrenergic signaling, FMLP signaling in neutrophils, 3-phosphoinositide biosynthesis and 
Fcy receptor-mediated phagocytosis. The top regulators include HNRNPA2B1 (p=1.73E-5), 
TSC22D3 (p=8.02E-5), ERBB4 (p=2.19E-4), NGF (p=6.23E-4) and LNX2 (p=6.23E-4). Others 
included CDK4, let-7, TP53, BTG2, and CCND1 (p<0.0001). Within these top 10 networks, several 
of our top target genes were identified to be involved. These were inclusive of: TRAF6, IGSF1 and 
IRAK1 in Group 1; HNRNPD in Group 2; RARB in Group 3; RFTN2 in Group 4; and NOVA1 in 
Group 5.  
 
Table 4.24: Top ten networks for hsa-miR-146a-5p target genes from Ingenity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Haematological system 
development and 
function, lymphoid tissue 
structure and 
development, tissue 
morphology 
26 Gene expression, cell 
morphology, organismal 
injury and abnormalities 
15 
Cancer, endocrine system 
disorders, organismal 
injury and abnormalities 
24 Cell cycle, cell death and 
survival, cellular growth 
and proliferation 
14 
Cancer, endocrine system 
disorders, organismal 
injury and abnormalities 
23 Developmental disorder, 
cancer, organismal injury 
and abnormalities 
14 
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Cell morphology, cellular 
function and 
maintenance, cell cycle 
16 Humoral immune 
response, immunological 
disease, protein synthesis 
13 
Organismal injury and 
abnormalities, 
cardiovascular disease, 
connective tissue 
disorders 
15 Cell death and survival, 
nervous system 
development and 
function, cellular growth 
and proliferation 
13 
 
 
4.9 hsa-miR-148b-3p 
The top twenty predicted genetic targets for hsa-miR-148b-3p are listed in Table 4.25. TargetScan 
identified 795 possible target genes, with a total of 882 conserved, and 263 poorly conserved possible 
binding sites. miRANDA-mirSVR identified 7413 possible targets, and DIANA-microT CDS found 
954 putative targets. Functional clustering analysis (DAVID) identified one genetic cluster, which 
contained S1PR1, ROBO1, ATP6AP2, B4GALT5 and PTPRA (enrichment score 0.45). GO analysis 
revealed over-representation of molecular functions such as protein binding, protein kinase activity, 
transcription factor activity and growth factor binding (p<0.0001). Biological functions including 
regulation of transcription, phosphorylation, cell cycle arrest, regulation of cell adhesion and DNA 
damage response regulation (p<0.0001). MiRSystem identified 679 putative target genes across at 
least three databases for miR-148b. Functional clustering of these genes found three enriched 
functional clusters (Refer to Table 4.26). None of the top twenty genes identified in this study were 
identified in these clusters.  
 
Table 4.25: Top twenty predicted targets for hsa-miR-148b-3p 
Target 
Gene 
Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
SOS2 SOS Ras/Rho guanine 
nucleotide exchange factor 2 
0.890 1.000 -2.670 Yes 
ATP6AP2 ATPase H+ transporting 
accessory protein 2 
0.960 0.999 -2.430 Yes 
BAI3  0.790 0.999 -2.510 No 
MEOX2 Mesenchyme homeobox 2 0.960 1.000 -2.160 No 
RBM24 RNA binding motif protein 24 0.820 0.900 -2.350 No 
C5orf30 Chromosome 5 open reading 
frame 30 
0.690 0.997 -2.370 No 
ROBO1 Roundabout guidance receptor 
1 
0.940 0.985 -2.060 No 
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OSBPL11 Oxysterol binding protein like 
11 
0.820 1.000 -2.100 Yes 
NPTN Neuroplastin 0.890 0.998 -2.030 No 
CDK19 Cyclin dependent kinase 19 0.980 0.992 -1.890 Yes 
USP33 Ubiquitin specific peptidase 33 0.760 0.977 -2.110 Yes 
PTEN Phosphatase and tensin 
homolog 
0.990 0.863 -1.970 No 
SNAP91 Synaptosome associated 
protein 91 
0.760 0.999 -1.990 No 
UBE2D1 Ubiquitin conjugating enzyme 
E2 D1 
0.580 0.825 -2.320 No 
HOMER1 Homer scaffolding protein 1 0.790 0.879 -1.990 No 
DMXL1 Dmx like 1 0.890 0.992 -1.740 No 
WDR47 WD repeat domain 47 0.660 0.931 -2.030 No 
S1PR1 Sphingosine 1-phosphate 
receptor 1 
0.940 0.997 -1.440 No 
ROCK1 Rho associated coiled-coil 
containing protein kinase 1 
>0.990 0.998 -1.290 Yes 
MITF Melanogenesis associated 
transcription factor 
0.980 0.991 -1.270 No 
 
 
Table 4.26: Functionally enriched target gene groups of hsa-miR-148b-3p identified by gene 
functional classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Protein kinase activity, ATP binding, 
intracellular signaling, phosphorylation 
5.83 11 
Zinc finger, transcription regulation, 
metal ion binding, DNA binding 
3.87 7 
GTP binding, protein transport, 
autophagy 
3.80 6 
 
IPA analysis identified 25 target gene networks, the top ten of which are detailed in Table 4.27. The 
predominant canonical pathways are PPAR/RXR activation, estrogen receptor signaling, 
Neuregulin signaling, B-cell receptor signaling and G-protein coupled receptor signaling. The main 
up-stream regulators included TP63 (p=2.20E-8), miR-148 (p=1.71E-7), STATa/b (p=1.52E-6), 
TP53 (p=2.33E-6) and NOX4 (p=3.06E-5). Others included MAP2K1, IGF1, MITF, AKT3, MYC, 
and PTEN (p<0.0001). Within the top 10 gene networks identified in IPA, MITF and ROCK1 were 
involved in Group 1; PTEN in Group 2; S1PR1 in Group 5; and CDK19 in Group 8.  
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Table 4.27: Top ten networks for hsa-miR-148b-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Celllular growth and 
proliferation, 
developmental disorder, 
gastrointestinal disease 
30 Gene expression, 
organismal survival, 
cellular growth and 
proliferation 
25 
Cardiovascular system 
development and 
function, organismal 
development, tissue 
morphology 
28 Cellular development, 
connective tissue 
development and 
function, tissue 
development 
25 
Protein synthesis, 
carbohydrate 
metabolism, molecular 
transport 
28 Cellular growth and 
proliferation, connective 
tissue development and 
function, tissue 
development 
22 
Cell death and survival, 
gene expression, cellular 
movement 
27 RNA damage and repair, 
molecular transport, 
RNA trafficking 
19 
Cardiovascular system 
development and 
function, organismal 
development, cellular 
movement 
25 Embryonic development, 
organismal development, 
tissue development 
16 
 
 
4.10 hsa-miR-150-5p 
The top twenty predicted target genes for hsa-miR-150-5p are given in Table 4.28. TargetScan 
identified 351 possible targets, with a total of 370 conserved and 404 poorly conserved binding sites. 
miRANDA-mirSVR found 9583 putative target genes, and DIANA microT-CDS found 1121 
possible targets. Functional clustering analysis (DAVID) found two clusters of genes: Group 1 
contained ZBTB4, NR2F2, FOXD3, ZEB1, MYB, MDM4 and RORB (enrichment score 1.90); while 
Group 2 included CMTM6, MTCH2 and SGMS1 (enrichment score 0.52).  
 
Table 4.28: Top twenty predicted targets for hsa-miR-150-5p 
Target 
gene 
Full Gene Name TargetScan 
Total context 
++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally validated 
[83] 
MYB MYB proto-oncogene -1.140 1.000 -3.210 Yes 
ADIPOR2 Adiponectin receptor 2 -0.750 0.996 -2.050 Yes 
MTCH2 Mitochondrial carrier 2 -0.660 0.990 -1.690 No 
MDM4 MDM4, p53 regulator -1.150 0.929 -1.210 No 
PDCD4 Programmed cell death 4 -0.400 0.926 -1.930 Yes 
ACO1 Aconitase 1 -0.790 0.870 -1.320 No 
ELOVL3 ELOVL fatty acid elongase 
3 
-0.480 0.980 -1.190 No 
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SKP1 S-phase kinase associated 
protein 1 
-0.670 0.877 -1.080 No 
TADA1 Transcriptional adaptor 1 -0.580 0.998 -1.020 No 
ZBTB4 Zinc finger and BTB domain 
containing 4 
-0.380 0.994 -1.200 No 
FOXD3 Forkhead box D3 -0.310 0.996 -1.250 No 
PDE7A Phosphodiesterase 7A -0.380 0.980 -1.150 No 
BASP1 Brain abundant membrane 
attached signal protein 1 
-0.380 0.892 -1.200 No 
SGMS1 Sphingomyelin synthase 1 -0.260 0.883 -1.280 No 
CMTM6 CKLF like MARVEL 
transmembrane domain 
containing 6 
-0.600 0.949 -0.860 No 
ZSWIM6 Zinc finger SWIM-type 
containing 6 
-0.180 0.932 -1.290 No 
NKX2-4 NK2 homeobox 4 -0.300 0.917 -1.180 No 
ZEB1 Zinc finger E-box binding 
homeobox 1 
-0.220 0.996 -1.180 Yes 
ADAM19 ADAM metallopeptidase 
domain 19 
-0.090 0.984 -1.260 No 
TEK TEK receptor tyrosine 
kinase 
-0.450 0.866 -0.980 No 
 
Interrogation of miRsystem revealed 290 possible target genes for hsa-miR-150-5p across at least 
three databases. Analysis of gene ontology of these genes found over-representation of molecular 
functions such as transcription factor activity, ubiquitin protein activity, protein kinase activity and 
DNA binding (p<0.0001), as well as of biological functions including regulation of transcription, cell 
migration, gene expression, Wnt signaling pathway and cell secretion (p<0.0001). Two functionally 
enriched clusters were identified (Refer to Table 4.29), however, none of these genes were identified 
in the top twenty predicted targets from this study.  
 
Table 4.29: Functionally enriched target gene groups of hsa-miR-150-5p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Nucleic acid binding, zinc finger, meta 
ion binding, transcription regulation 
2.20 7 
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IPA analysis identified 25 target gene networks, and the top 10 of these are detailed in Table 4.30. 
The highest ranking canonical pathways included molecular mechanisms of cancer, GNRH signaling, 
HGF signaling, CDK5 signaling and Wnt/-catenin signaling. The predominant up-stream regulators 
included ZFAS1 (p=2.40E-6), miR-185 (p=1.28E-4), RPLP2 (p=1.80E-4), ITGA6 (p=2.68E-4) and 
FOXO3 (p=5.45E-4). Others included TP63, EGFR, E2F1, IL7R, and MYC (p<0.0001). Several of 
the top 20 gene targets identified in this study are involved in the top 10 networks identified in IPA. 
These include: MYB in Group 1; ZEB1 in Group 3; ADAM19 in Group 4; ADIPOR2 and SGMS1 
in Group 6; and PDCD4 and ELOL3 in Group 9.  
 
Table 4.30: Top ten networks for hsa-miR-150-5p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Digestive system 
development and 
function, hepatic system 
development and 
function, organ 
morphology 
24 Behaviour, nervous 
system development and 
function, small molecule 
biochemistry 
14 
Organismal functions, 
gene expression, 
behavior 
23 Cancer, organismal 
injury and abnormalities, 
cellular development 
14 
Cellular development, 
cellular growth and 
proliferation, 
haematological system 
development and 
function 
21 Endocrine system 
disorders, organ 
morphology, organismal 
injury and abnormalities 
12 
Cellular growth and 
proliferation, embryonic 
development, cellular 
development 
15 Protein synthesis, cancer, 
cell death and survival 
12 
Cell death and survival, 
cellular development, 
cellular function and 
maintenance 
15 Cell morphology, organ 
morphology, skeletal 
muscular system 
development and 
function 
12 
 
 
4.11 hsa-miR-155-5p 
The top twenty potential target genes for hsa-miR-155-5p are listed in Table 4.31. DIANA microT-
CDS identified 1090 possible targets, and miRANDA-mirSVR found 5455 possible gene targets. 
TargetScan identified 552 possible targets, with 592 conserved and 239 poorly conserved potential 
binding sites. Functional clustering analysis (DAVID) revealed one genetic functional cluster, 
containing BACH1, TSHZ3, HIVEP2, CEBPB, IRF2BP2, JARID2, ARID2 and ZIC3 (enrichment 
score 1.61).  
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Table 4.31: Top twenty predicted targets for hsa-miR-155-5p 
Target Gene Full Gene Name TargetScan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRAND
A score 
mirSVR 
Experimentally 
validated [83] 
ARID2 AT-rich interaction domain 2 0.710 0.999 -2.970 Yes 
HIVEP2 Human immunodeficiency virus 
type I enhancer binding protein 2 
0.610 0.977 -2.810 Yes 
BACH1 BTB domain and CNC homolog 1 0.790 0.994 -2.400 Yes 
PICALM Phosphatidylinositol binding 
clathrin assembly protein 
0.610 0.933 -2.440 Yes 
ZIC3 Zic family member 3 0.620 0.995 -2.240 Yes 
GABRA1 Gamma-aminubutyric acid type A 
receptor alpha 1 subunit 
0.370 0.959 -2.460 No 
TSHZ3 Teashirt zinc finger homeobox 3 0.810 1.000 -1.950 Yes 
JARID2 Jumonji and AT-rich interaction 
domain containing 2 
0.820 1.000 -1.900 Yes 
LRP1B LDL receptor related protein 1B 0.380 0.999 -2.220 No 
RBMS3 RNA binding motif single stranded 
interacting protein 3 
0.590 0.894 -2.110 No 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
0.550 0.998 -1.970 Yes 
WEE1 WEE1 G2 checkpoint kinase 0.940 0.997 -1.410 Yes 
FBXO30 F-box protein 30 0.500 0.997 -1.340 No 
MYB1  0.410 0.766 -2.070 No 
DHX40 DEAH-box helicase 40 0.710 0.998 -1.280 Yes 
CEBPB CCAAT/enhancer binding protein 
beta 
0.770 0.990 -1.200 Yes 
TMEM202 Transmembrane protein 202 <0.100 0.881 -1.960 No 
TRIM23 Tripartitie motif containing 23 <0.100 0.842 -1.940 No 
FBXO33 F-box protein 33 0.500 0.997 -1.340 No 
IRF2BP2 Interferon regulatory factor 2 
binding protein 2 
0.390 1.000 -1.320 Yes 
 
429 potential target genes were identified for hsa-miR-155-5p using miRSystem, across at least three 
databases. GO analysis of these genes identified over-representation of molecular functions such as 
transcription factor activity, protein and DNA binding, and protein kinase activity (p<0.0001), as well 
as biological functions including regulation of transcription and the cell cycle, and intracellular 
signaling (p<0.0001). Functional clustering analysis identified one enriched functional cluster (Refer 
to Table 4.32). Within this cluster, IRF2BP2 and HIVEP2 were also identified in the top twenty 
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targets identified in this study. A further gene, TMEM202, was found in another functionally enriched 
cluster (enrichment score 0.14).  
 
Table 4.32: Functionally enriched target gene groups of hsa-miR-155-5p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Transcription regulation, zinc finger, 
metal binding, DNA binding 
5.25 18 
 
IPA analysis identified 25 gene networks, and the top 10 are listed in Table 4.33. The predominant 
canonical pathways involved include T-cell receptor signaling, molecular mechanisms of cancer, 
TGF--signaling, IGF-1 signaling and regulation of IL-2 expression. The main up-stream regulators 
include miR-155 (p=7.00E-10), COL18A1 (p=6.16E-6), TGFBR2 (p=4.86E-5), miR-17 (p=1.78E-
4) and PSMD10 (p=1.78E-4). Others include TGFB1, Akt, PI3K, CCND1, CDK4, MAP2K1, and 
EGFR (p<0.0001). Several of our top 20 predicted targets were identified to be involved in gene 
networks identified in IPA. These include TSHZ3 and IRF2BP2 in Group 1; FOS in Group 2; ARID2 
and WEE1 in Group 3; and PICALM in Group 4. Several of the top 20 predicted targets identified in 
this study were identified in networks 11 (BACH1) and 12 (GABRA1 and FBXO33). Network 11 is 
involved in cellular functions such as cell cycle, DNA replication, recombination and repair, cellular 
assembly and organization, and contained 13 genes. Network 12 is involved in amino acid 
metabolism, small molecule biochemistry, and DNA replication, recombination and repair; and also 
contained 13 genes.  
 
Table 4.33: Top ten networks for hsa-miR-155-5p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Gene expression, cellular 
development, 
haematoogical system 
development and 
function 
29 Nervous system 
development and 
function, tissue 
morphology, cellular 
movement 
20 
Cell cycle, hair and skin 
development and 
function, organ 
development 
25 Cancer, haemtological 
disease, immunological 
disease 
16 
Gene expression, cellular 
compromise, 
haematological system 
development and 
function 
25 Cell morphology, renal 
and urological system 
development and 
function, cellular 
assembly and 
organization 
15 
Developmental disorder, 
cardiovascular disease, 
haematological disease 
24 Cellular development, 
cell death and survival, 
embryonic development 
15 
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Cellular development, 
cellular growth and 
proliferation, 
cardiovascular system 
development and 
function 
24 Cancer, organismal 
injury and abnormalities, 
cell morphology 
14 
 
 
4.12 hsa-miR-205-3p 
The top twenty predicted target genes for hsa-miR-205-3p are listed in Table 4.34. TargetScan 
investigation revealed 6551 possible targets, with a total of 10996 possible binding sites. miRANDA-
mirSVR found 7894 potential gene targets, while DIANA microT-CDS found 2283 possible targets. 
Functional clustering analysis (DAVID) found two clusters of genes: Group 1 included SUZ12, 
NR3C2, MDM4 and MSL2 (enrichment score 0.75), while Group 2 contained PTCHD1, CDH11, 
TMEM144 and SLC35A3 (enrichment score 0.24).  
 
Table 4.34: Top twenty predicted targets for hsa-miR-205-3p 
Target 
gene 
Full Gene Name TargetScan 
Total 
context ++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
GCC2 GRIP and coiled-coil domain 
containing 2 
-0.060 0.964 -1.930 No 
ZFYVE16 Zinc finger FYVE-type 
containing 16 
-0.030 0.839 -1.930 No 
TMEM144 Transmembrane protein 144 -0.060 0.813 -1.820 No 
PLCB1 Phospholipase C beta 1 -0.060 0.854 -1.770 No 
DHFR Dihydrofolate reductase -0.040 0.714 -1.820 No 
CUL5 Cullin 5 -0.050 0.963 -1.550 Yes 
NR3C2 Nuclear receptor subfamily 3 
group C member 2 
-0.030 0.745 -1.730 No 
PTCHD1 Patched domain containing 1 -0.060 0.795 -1.620 No 
SUZ12 SUZ12 polycomb repressive 
complex 2 subunit 
-0.120 0.996 -1.350 No 
MSL2 Male-specific lethal 2 homolog -0.050 0.709 -1.700 No 
FGD4 FYVE, RhoGEF and PH domain 
containing 4 
-0.040 0.797 -1.610 No 
SH3GL3 SH3 domain containing GRB2 
like 3, endophilin A3 
-0.170 0.944 -1.320 No 
CDK19 Cyclin dependent kinase 19 -0.090 0.807 -1.440 No 
MDM4 MDM4, p53 regulator -0.050 0.940 -1.330 No 
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FAM35A Family with sequence similarity 
35 member A 
-0.050 0.975 -1.250 No 
FAM19A2 Family with sequence similarity 
19 member A2 
-0.020 0.772 -1.840 No 
CDH11 Cadherin 11 -0.060 0.861 -1.300 No 
SLC35A3 Solute carrier family 35 member 
3 
-0.080 0.858 -1.300 No 
TRNT1 tRNA nucleotidyl transferase 1 -0.030 0.754 -1.390 No 
SBF2 SET binding factor 2 -0.010 0.716 -1.320 No 
 
miRSystem interrogation revealed 497 potential target genes for hsa-miR-205-3p across three 
databases. GO analysis of these genes found that biological functions such as regulation of 
transcription and gene expression, protein kinase activity and intracellular signal transduction were 
over-represented (p<0.0001), as well as molecular functions including enzyme and protein biding, 
transcription coactivator and transcription factor binding, and protein transport (p<0.0001). Two 
functionally enriched gene clusters were identified (Refer to Table 4.35), however, there were no 
similarities between genes in these clusters and the top twenty potential targets identified here.  
 
Table 4.35: Functionally enriched target gene groups of hsa-miR-205-3p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Protein kinase activity, phosphorylation, 
intracellular signal transduction, ATP 
binding 
4.04 7 
Zinc finger, DNA binding, transcription 
regulation, cell division 
3.18 15 
 
IPA analysis identified 25 gene networks, and the top 10 are listed in Table 4.36. The top canonical 
pathways involved include RAR activation, Neuregulin signaling, HIPPO signaling and Fcy receptor-
mediated phagocytosis. The top up-stream regulators include TP53 (p=1.86E-5), Estrogen receptors 
(p=5.43E-5), miR-34a (p=8.30E-5), CTBP2 (p=1.21E-4) and miR-205 (p=2.37E-4). Others included 
KRAS, MNT5A, TGFB1, and TNF (p<0.0001). Several genes identified in this study were similarly 
identified to be involved in the top gene networks identified in IPA. These include SUZ12 in Group 
1; CUL5 and NR3C2 in Group 5; CDH11 in Group 6; MSL2 in Group 9; and ZFYVE16 in Group 
10.  
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Table 4.36: Top ten networks for hsa-miR-205-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Cellular assembly and 
organization, RNA post-
transcriptional 
modification, 
developmental disorder 
31 Cellular development, 
cellular growth and 
proliferation, embryonic 
development 
19 
Cellular movement, 
tissue development, 
cardiovascular system 
development and 
function 
29 Cell death and survival, 
connective tissue 
disorders, 
haematological disease 
19 
Cellular assembly and 
organization, cell cycle, 
DNA replication, 
recombination and repair 
28 Infectious diseases, 
cancer, organismal injury 
and abnormalities 
16 
Lymphoid tissue 
structure and 
development, cell death 
and survival, cellular 
growth and proliferation 
26 Cellular response to 
therapeutics, DNA 
replication, 
recombination and repair, 
cell morphology 
15 
Cancer, neurological 
disease, cell morphology 
23 Embryonic development, 
organismal development, 
tissue development 
15 
 
4.13 hsa-miR-342-3p 
The top twenty predicted gene targets of hsa-miR-342-3p are given in Table 4.37. miRANDA-
mirSVR investigation yielded 7724 possible gene targets, while DIANA microT-CDS found 992 
possible targets. TargetScan found 315 potential transcript targets, with a total of 317 conserved and 
211 poorly conserved possible binding sites. Functional analysis (DAVID) identified one functional 
genetic cluster, containing BTN2A1, GOLM1, PRIMA1, MTDH, FXYD3 and CA12 (enrichment 
score 0.38).  
 
Table 4.37: Top twenty predicted targets for hsa-miR-342-3p 
Target 
gene 
Full Gene Name TargetScan 
Total 
context ++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
ID4 Inhibitor of DNA binding 4, HLH 
protein 
-0.510 0.977 -1.530 Yes 
BTN2A1 Butyrophilin subfamily 2 
member A1 
-0.690 0.940 -1.370 No 
TIA1 TIA1 cytotoxic granule 
associated RNA binding protein 
-0.540 0.998 -1.420 No 
UBE2D2 Uniquitin conjugating enzyme E2 
D2 
-0.650 0.946 -1.220 No 
KDM6B Lysine demethylase 6B -0.410 1.000 -1.300 No 
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FUT8 Fucosyltransferase 8 -0.380 0.977 -1.320 No 
MATN1 Matrilin 1, cartilage matrix 
protein 
-0.520 0.933 -1.240 No 
MRFAP1 Morf4 family associated protein 1 -0.530 0.801 -1.230 No 
EP300 E1A binding protein p300 -0.280 0.999 -1.260 No 
FXYD3 FXYD domain containing ion 
transport regulator 3 
-0.500 0.889 -1.100 No 
ZFR Zinc finger RNA binding protein -0.220 0.960 -1.280 No 
RGS4 Regulator of G-protein signalling 
4 
-0.730 0.886 -0.840 Yes 
FOSB FosB proto-oncogene, AP-1 
trnascription factor subunit 
-0.710 0.978 -0.730 No 
NBEA Neurobeachin -0.210 0.957 -1.200 No 
GOLM1 Golgi membrane protein 1 -0.320 0.975 -0.990 No 
PDCFRA  -0.230 1.000 -0.980 No 
MTDH Metadherin -0.340 0.877 -0.910 No 
CA12 Carbonic anhydrase 12 -0.370 0.997 -0.740 No 
NKX2-2 NKX2-2 antisense RNA 1 -0.250 0.767 -1.080 No 
TRMT2A tRNA methyltransferase 2 
homolog A 
-0.020 0.854 -1.190 No 
 
276 genes across at least three databases were identified using miRSystem to be potential targets of 
hsa-miR-342-3p. GO analysis of these genes found that molecular functions such as protein kinase 
binding, DNA binding, transcription factor activity and receptor signaling were over-represented 
(p<0.0001), as were biological functions such as cell migration, regulation of transcription, and cell 
proliferation and differentiation (p<0.0001). One functionally enriched gene cluster was identified 
(Refer to Table 4.38), but there were no similarities with the top twenty predicted targets identified 
in this study.  
 
Table 4.38: Functionally enriched target gene groups of hsa-miR-342-3p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Transcription regulation, zinc finger, 
metal binding, DNA binding 
2.24 10 
 
IPA analysis identified 25 gene networks, and the top 10 are detailed in Table 4.39. The top canonical 
pathways included ERK5 signaling, Tissue factor in cancer, molecular mechanisms of cancer, and 
Ephrin receptor signaling. The predominant up-stream regulators included GH (p=2.99E-5), EXH2 
(p=3.01E-5), PDGF BB (p=4.88E-5), SMAD4 (p=1.25E-4) and CTNNB1 (p=1.37E-4). Others 
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included IL6, BCL6, EGFR, NR3C1, BCL2 and IL6R (p<0.0001). Within the top 10 gene networks 
identified in IPA, several of our top target genes were found to be involved. These include: FOSB in 
Group 1; EP300 and CA12 in Group 2; MTDH and NKX2-2 in Group 3; ID4 and UBE2D2 in Group 
5; MRFAP1 in Group 6; UBE2D2 and KDM6B in Group 8; and MATN1 in Group 10.  
 
Table 4.39: Top ten networks for hsa-miR-342-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Cellular movement, 
cellular growth and 
proliferation, cell death 
and survival 
29 Cell cycle, connective 
tissue development and 
function, hepatic system 
development and 
function 
13 
Cell cycle, 
cardiovascular disease, 
organismal injury and 
abnormalities 
25 Cancer, cellular 
movement, organismal 
injury and abnormalities 
13 
Post-translational 
modification, 
cardiovascular disease, 
cardiovascular system 
development and 
function 
21 Cell death and survival, 
connective tissue 
disorders, developmental 
disorder 
13 
Organ morphology, 
organismal development, 
reproductive system 
development and 
function 
15 Cellular function and 
maintenance, molecular 
transport, small molecule 
biochemistry 
13 
Cancer, neurological 
disease, organismal 
injury and abnormalities 
13 Embryonic development, 
organismal development, 
gastrointestinal disease 
12 
 
4.14 hsa-miR-361-3p 
The top twenty predicted gene targets for hsa-miR-361-3p are listed in Table 4.40. miRANDA-
mirSVR identified 7814 possible target genes, while DIANA microT-CDS found 238 potential 
targets. TargetScan identified 5163 possible gene targets, with a total of 7850 potential binding sites. 
Functional gene clustering analysis (DAVID) identified one cluster, which included ENTPD3, 
UGT8, MFSD6, KCNMA1, CADM4, PTGER2 and GRID1 (enrichment score 0.8).  
 
Table 4.40: Top twenty predicted targets for hsa-miR-361-3p 
Target 
Gene 
Full Gene Name TargetScan  
Total 
context ++ 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
CADM4 Cell adhesion molecule 4 -0.800 0.982 -1.280 No 
PTPLA C-hydroxyacyl-CoA dehydratase 1 -0.730 0.999 -1.320 No 
KCNMA1 Potassium calcium-activated 
channel subfamily M alpha 1 
-0.010 0.997 -1.730 No 
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ABI1 Abl interactor 1 -0.510 0.920 -1.190 No 
HOXA10 Homeobox A10 -0.510 0.882 -1.220 No 
PRAMEF8 PRAME family member 8 -0.650 0.959 -0.850 No 
GGCT Gamma-glutamylcyclotransferase -0.580 0.798 -1.060 No 
MFSD6 Major facilitator superfamily 
domain containing 6 
-0.340 0.942 -1.140 Yes 
SETD6 SET domain containing 6 -0.550 0.949 -0.890 No 
MAP3K10 Mitogen-activated protein kinase 
kinase kinase 10 
-0.550 0.795 -1.030 No 
BATF1 Basuc leucine zipper ATF-like 
transcription factor 
-0.340 0.865 -1.080 No 
UGT8 UDP glycosyltransferase 8 -0.380 0.884 -1.010 No 
NUBPL Nucleotide binding protein like -0.390 -0.981 -0.820 No 
PTGER2 Prostaglandin E receptor 2 -0.360 0.720 -1.080 No 
OSR2 Odd-skipped related transcription 
factor 2 
-0.520 0.737 -0.890 No 
TMEM189-
YBE2V1 
TMEM189-UBE2V1 readthrough -0.330 0.790 -1.000 No 
SENP1 SUMO1/sentrin specific peptidase 
1 
-0.420 0.869 -0.830 No 
TOMM20 Translocase of outer mitochondrial 
membrane 20 
-0.570 0.927 -0.550 No 
TMEM35 Transmembrane protein 35 -0.470 0.905 -0.670 No 
HOXC6 Homeobox C6 -0.320 0.932 -0.790 No 
 
132 putative target genes were identified across at least three databases using miRSystem. Biological 
functions including transcription regulation, cell adhesion, synaptic transmission, and response to 
growth factors were over-represented on GO analysis (p<0.0001). Molecular functions were also 
over-represented including transcription factor and coactivator activity, DNA binding and protein 
kinase activity (p<0.0001). No functionally enriched gene clusters were identified.  
 
IPA analysis found 16 gene networks, the top 10 of which are listed in Table 4.41. The top canonical 
pathways identified included glucocorticoid receptor signaling, calcium signaling, Ephrin receptor 
signaling, B-cell receptor signaling and RAR activation. Top regulators of these networks include 
miR-34 (p=6.27E-4), RUNX1 (p=1.35E-3), ESR2 (p=1.86E-3), miR-218 (p=2.90E-3) and DDX5 
(p=2.90E-3). Others include CCDC8, JAK2, and PTEN (p<0.0001). Several of the top 20 target genes 
identified in this study were found to be involved in the top gene networks (Refer to Table 4.41). 
These included KCNMA1 in Group 1; MFSD6 in Group 2; OSR2 in Group 4; HOXA10 in Group 5; 
and ABI1 and HOXC6 in Group 7.  
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Table 4.41: Top ten networks for hsa-miR-361-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Gene expression, 
connective tissue 
development and 
function, tissue 
development 
22 Cellular movement, 
cardiovascular system 
development and 
function, organismal 
development 
11 
Organismal injury and 
abnormalities, renal 
degeneration, renal and 
urological disease 
14 Cellular function and 
maintenance, molecular 
transport, small molecule 
biochemistry 
10 
Nervous system 
development and 
function, embryonic 
development, organismal 
development 
12 Developmental disorder, 
hereditary disorder, 
nervous system 
development and 
function 
1 
Cell cycle, cell-to-cell 
signaling and interaction, 
cellular growth and 
proliferation 
12 Cell signaling, cancer, 
organismal injury and 
abnormalities 
1 
Cell morphology, cell 
cycle, embryonic 
development 
11 Cell cycle, cell-to-cell 
signaling and interaction, 
cellular assembly and 
organization 
1 
 
4.15 hsa-miR-363-3p 
The top twenty predicted gene targets for hsa-miR-363-3p are listed in Table 4.42. TargetScan found 
1037 possible target genes, with a total of 1163 conserved and 323 poorly conserved binding sites. 
DIANA microT-CDS found 861 possible target genes, while miRANDA-mirSVR found 6386 
putative gene targets. Functional clustering analysis (DAVID) identified one functional cluster, 
including MAN2A1, LHFPL2, CHST7, B3GALT2, SLC17A6, SLC12A5, CD69 and BTLA 
(enrichment score 1.02).  
 
Table 4.42: Top twenty predicted targets for hsa-miR-363-3p 
Target Gene Full Gene Name Targetscan 
Aggregate 
PCT 
DIANA 
score 
miTG 
miRANDA 
score 
mirSVR 
Experimentally 
validated [83] 
CD69 CD69 molecule >0.990 0.998 -3.660 No 
MAN2A1 Mannosidase alpha class 2A 
member 1 
>0.990 0.980 -2.740 No 
FBXW7 F-box and WD repeat domain 
containing 7 
0.980 0.992 -2.440 No 
SLC12A5 Solute carrier family 12 member 5 0.980 0.992 -2.340 Yes 
KLF4 Kruppel like factor 4 0.950 0.985 -2.360 No 
FNIP1 Folliculin interacting protein 1 0.990 0.999 -2.180 Yes 
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MYO1B Myosin 1B 0.970 0.992 -2.150 Yes 
MORC3 MORC family CW-type zinc 
finger 3 
0.910 0.971 -2.200 No 
KIAA1432 RIC1 homolog, RAB6A GEF 
complex partner 1 
0.990 0.974 -2.110 No 
MAP2K4 Mitogen-activated protein kinase 
kinase 4 
>0.990 0.989 -2.080 Yes 
SLC17A6 Solute carrier family 17 member 6 0.740 0.974 -2.220 No 
RBM47 RNA binding motif protein 47 0.730 0.976 -2.190 No 
RNF38 Ring finger protein 38 0.860 0.974 -1.850 No 
KLHL14 Kelch like family member 14 0.950 0.894 -1.820 No 
RAB23 RAB23, member RAS oncogene 
family 
0.990 0.891 -1.760 No 
ARMC1 Armadillo repeat containing 1 0.940 0.956 -1.650 No 
BTG2 BTG anti-proliferation factor 2 >0.990 0.943 -1.440 Yes 
BTLA B and T lymphocyte associated 0.460 0.833 -2.070 No 
HIPK3 Homeodomain interacting protein 
kinase 3 
>0.990 1.000 -1.370 No 
LHFPL2 Lipoma HMGIC fusion partner-
like 2 
>0.990 0.955 -1.400 Yes 
 
miRSystem identified 573 potential target genes for hsa-miR-363-3p across at least three databases. 
GO analysis of this gene list found that biological functions such as cell proliferation, transcription, 
cell adhesion and synaptic transmission (p<0.0001), as well as molecular functions including protein 
binding, protein kinase activity, transcription factor activity and DNA binding (p<0.0001) were over-
represented. Three functionally enriched gene clusters were identified (Refer to Table 4.43). Of the 
predicted targets identified in this study, HIPK3 was identified in functional cluster 2.  
 
Table 4.43: Functionally enriched target gene groups of hsa-miR-363-3p identified by gene functional 
classification in DAVID 
Functional classification group 
 
Enrichment score Number of target genes 
Membrane composition and function, 
intracellular signal transduction 
4.76 10 
Protein kinase activity, nucleotide 
binding, cytoskeleton, cell membrane 
4.66 5 
Zinc finger, transcription regulation, 
metal ion binding, cell division 
3.65 10 
 
IPA analysis identified 25 networks, and the top 10 are listed in Table 4.44. Top canonical pathways 
involved include synaptic long term potentiation, calcium signaling, molecular mechanisms of cancer 
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and 3-phosphoinositide biosynthesis. The top regulators were miR-486 (p=4.58E-10), miR-25 
(p=1.51E-6), MYOC (p=9.10E-6), CST5 (p=5.47E-5) and miR-32 (p=7.35E-5). Others included 
TGFB1, CTBP2, JARID2 TBPL1, NR3C1, TNF and IL12B (p<0.0001). Within the top 10 gene 
networks identified in IPA, several of the top 20 genes identified in this study were found to be 
involved. These include: MAP2K4 and BTG2 in Group 1; CD69 in Group 2; FBXW7 in Group 3; 
RBM47 in Group 8; and KLF4 and LHFPL2 in Group 10.  
 
Table 4.44: Top ten networks for hsa-miR-363-3p target genes from Ingenuity Pathway Analysis 
Network functions Number of Genes Network functions  Number of Genes 
Cellular growth and 
proliferation, cancer, 
organismal injury and 
abnormalities 
29 Cancer, organismal 
injury and abnormalities, 
neurological disease 
18 
Connective tissue 
disorders, organismal 
injury and abnormalities, 
skeletal muscular 
disorders 
27 Cellular assembly and 
organization, cellular 
function and 
maintenance, protein 
trafficking 
18 
Gene expression, cell 
cycle, developmental 
disorder 
26 Dermatological diseases 
and conditions, 
inflammatory disease, 
inflammatory response 
14 
Cancer, haematological 
disease, organismal 
injury and abnormalities 
25 Cardiovascular disease, 
congenital heart 
anomaly, developmental 
disorder 
16 
Cellular movement, cell-
to-cell signaling and 
interaction, 
haematological system 
development and 
function 
21 Gene expression, cellular 
growth and proliferation, 
organismal development 
16 
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CHAPTER FIVE: DISCUSSION 
5.1 Introduction 
Squamous cell carcinoma of mucosal sites in the head and neck is a complex disease. Clinically, 
patients with HPV-associated tumours in the oropharynx tend to have a distinct profile: younger, and 
higher functioning. Further, they have also demonstrated an enhanced response to chemotherapy and 
radiotherapy than patients with HPV-negative tumours; and improved overall survival rates [5, 13, 
14, 22]. While we have a firm understanding of the clinical consequences of a HPV-associated tumour 
in the oropharynx, the pathobiology of these tumours remains poorly understood. As clinical trials 
aimed at ensuring appropriateness of therapy, including de-escalation of therapy when suitable, are 
presently ongoing [1, 6], it is imperative that we fully understand the molecular mechanisms 
underlying carcinogenesis in both HPV-positive and HPV-negative tumours, to allow identification 
of patients who may require more intensive therapy. While a significant proportion of HNSCC 
patients tend to present with either more locally advanced disease (T stage III/IV) or with regional 
nodal disease at diagnosis [4, 5], as yet there is no clinically applicable tool such as a population wide 
screening tool, to enable an earlier diagnosis. There is enormous potential for miRNAs to fill these 
gaps as clinical biomarkers in head and neck cancer.  
 
5.2 Discussion of profiling results  
5.2.1 HPV-positive tumours demonstrate altered microRNA expression 
In this study, a HPV-positive tumour was defined as positive for HPV DNA with positive staining of 
p16INK4a on immunohistochemistry. A number of miRNAs were differentially expressed between 
HPV-positive and HPV-negative tumours in the oropharynx. These were: hsa-miR-15b-5p, hsa-miR-
16-2-3p, hsa-miR-20b-5p, hsa-miR-30e-5p, hsa-miR-142-3p, hsa-miR-361-3p and hsa-miR-363-3p. 
Several of these, hsa-miR-15b-5p, hsa-miR-16-2-3p, hsa-miR-20b-5p and hsa-miR-363-3p have 
consistently been reported as upregulated across previous studies investigating HPV-associated 
HNSCC (Refer to Table 5.1) [12, 55, 58, 66, 89]. Two miRNAs which have been identified as 
differentially expressed in this study have not been previously reported in HPV-positive head and 
neck cancers, hsa-miR-30e-5p and hsa-miR-361-3p. Finally, hsa-miR-142-3p was identified as up-
regulated in HPV-positive tumours in the present study, but has only previously been reported as 
down-regulated in these tumours in one study on head and neck cell lines [66]. This needs to be 
interpreted with caution as studies comparing cell lines with human tissue have identified differences 
in cellular miRNA expression; as the cells may not accurately depict in-vivo intra-cellular changes 
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[57]. Further studies will determine whether miR-142 is up- or down-regulated in HPV-associated 
HNSCC.  
 
Table 5.1: Comparison of miRNA profiling results with previous literature 
miRNA  Direction of Change Up-regulated Down-regulated 
hsa-miR-15b Up Lajer et al [12], Miller et al [89]  
hsa-miR-16 Up Lajer et al [12], Miller et al [89]  
hsa-miR-20b Up Lajer et al [12], Hui [90], Miller et al [89]  
hsa-miR-30e Up   
hsa-miR-142 Up  Wald et al [66] 
hsa-miR-361 Up   
hsa-miR-363 Up Lajer et al [58], Lajer et al [12], Wald 2011 
[66], Miller et al [89] 
 
 
Two miRNAs were identified as up-regulated across all subsites in HPV-positive tumours when 
compared with HPV-negative tumours. These were: hsa-miR-16-2-3p and hsa-miR-20b-5p. The 
majority of studies looking at the differing miRNA expression in HPV-positive tumours have only 
included tumours of the oropharynx (Refer to Table 1.1), but Lajer et al [12] also identified these two 
miRNAs to be differentially expressed across all sites, as in the present study.  
 
5.2.2 MicroRNA alteration and p16 INK4a status 
In the literature, the definition of a HPV-associated tumour is variable, and can include the use of 
p16INK4a status alone, in combination with HPV DNA status, HPV DNA status alone, or E6 and E7 
mRNA status. The latter of these is considered the gold standard for defining HPV status in research, 
although use of a combination of HPV DNA and p16INK4a immunohistochemistry has been shown to 
be equivalent in detecting clinically significant infections [91]. Clinically however, only the p16INK4a 
status of a tumour is used as a surrogate marker for HPV status. This study identified only one miRNA 
which was dysregulated between tumours positive and negative for p16INK4a across all subsites: miR-
16. There was no difference in miRNA expression with p16INK4a status at any individual subsite, 
including the oropharynx. Hui et al [90] defined a HPV-positive tumour as one that is positive for 
p16INK4a only, but only identified miR-9 and miR-20b to be dysregulated.  
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5.2.3 HPV-positive smokers demonstrate altered microRNA expression 
HPV-positive tumours occurring in patients with a history of heavy tobacco smoking are a distinct 
entity. A history of cigarette smoking both increases the risk of developing a HPV-related tumour [7, 
92], and negatively influences survival [8, 93, 94]. The present study has identified hsa-miR-20b-5p 
to be over-expressed in smokers with oropharyngeal tumours, and hsa-miR-363-3p to be over-
expressed in smokers across all subsites. In a multi-variate analysis of HPV status and smoking status, 
only hsa-miR-150-5p was significantly differentially expressed, being up-regulated in oropharyngeal 
HPV-positive tumours. To date, potential differences in miRNA expression with smoking status in 
combination with HPV tumour status has not specifically been addressed in the literature. However, 
several studies have investigated the difference in miRNA expression between smokers and non-
smokers. Some authors [95] have identified no difference between the two groups, while many, with 
particular focus on lung cancers, have identified a number of differences in tumours that have 
exposure to nicotine [96]. 
 
5.2.4 Alcohol and association with microRNA expression 
A number of miRNAs were identified to be differentially regulated in tumours of patients who were 
heavy alcohol consumers, compared with patients who abstained from alcohol consumption. Several 
studies have investigated the relationship of miRNA expression to alcohol use in HNSCC patients. 
In head and neck cancers, miR-375 has previously been shown to be correlate significantly with 
alcohol consumption [64]. Another study found long-term exposure of tumour cells to ethanol 
resulted in up-regulation of miR-30a, miR-934, miR-3164 and miR-3178 [97]. However, while we 
identified several miRNAs which were differentially expressed in HPV-related tumours in patients 
who also consumed alcohol in a multivariate analysis, there is no previous literature with which to 
compare these findings. Further research is therefore warranted to confirm or refute these results.  
 
5.2.5 Association of microiRNA expression with recurrence of  disease 
Several miRNAs were identified to be associated with recurrence of the primary tumour. When 
compared to the previous literature, only miR-205 has previously been reported as dysregulated in 
association with loco-regional recurrence of disease [60, 61]. However, very few studies have 
evaluated miRNA expression in the context of recurrence of the primary tumour, and therefore 
although miR-205 demonstrates promise in that it has been consistently reported across several 
studies, further research in this area is needed.  
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5.2.6 MicroRNAs and association with survival 
Both disease-free and recurrence-free survival were analysed in this study, and a number of miRNAs 
were identified to be differentially expressed in each analysis. Unfortunately, as this study focused 
on evaluating differential expression between HPV-positive and negative tumours, the miRNAs 
chosen for further validation in this study are not ones which have been reported to correlate with 
survival and prognosis previously in HNSCC studies. Therefore, it is difficult to draw conclusions 
from comparison of the current results with those of previous studies. However, this study has 
identified several miRNAs which demonstrate promise as prognostic markers. In particular, hsa-miR-
16-2-3p, hsa-miR-20b-5p and hsa-miR-363-3p. hsa-miR-16-2-3p was found to correlate with RFS in 
oropharyngeal tumours both when HPV status was considered and when it was not, possibly 
indicating that this miRNA may be suitable for further research as a prognostic biomarker in 
oropharyngeal SCCs. DFS was shown to correlate with expression of hsa-miR-20b-5p when HPV 
tumour status is accounted for across all subsites and in the oral cavity; however, interestingly, only 
when HPV status was not considered in analysis of oropharyngeal tumours. Again, this warrants 
further study, and consideration as a potential prognostic biomarker. Finally, in HPV-negative oral 
cavity tumours; apart from smoking status, currently, there is clinically no way of determining which 
patients will have a poorer prognosis. This study identified that miR-363 correlated significantly with 
DFS in these patients, again potentially indicating that this miRNA may hold promise for use as a 
prognostic biomarker in this tumour cohort.  
 
5.3 The genomic landscape of HNSCC 
A number of studies have focused on genomic profiling of head and neck cancers in recent years, and 
a smaller number again have investigated the difference in genomic differences between HPV-
positive and HPV-negative tumours. In particular, analysis of the cancer genome atlas of head and 
neck cancers (TGCA), which is ongoing currently, will provide the most comprehensive and 
integrative genomic profile of head and neck cancers [98-100]. There are a number of genes which 
are differentially expressed between HPV-positive and HPV-negative tumours; as well as several 
commonly dysregulated intracellular signaling pathways which are abnormally regulated in HPV-
associated HNSCC when compared with HPV-unrelated tumours. These pathways are important for 
future research to focus on, as if potentially drugable gene targets are identified, this may have 
important clinical implications for therapeutics in HPV-related head and neck cancer. It is clear from 
both this study and the literature that as a result of the nature of miRNA::mRNA interactions, one 
miRNA is able to target a number of mRNA strands, and similarly, one mRNA is potentially targeted 
by a number of miRNAs. This biological redundancy enables multiple points within a single cellular 
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pathway to be disrupted, with subsequently multiple points at which steps towards carcinogenesis 
may occur.  
 
In this study, IPA pathway analysis was performed in order to determine the most commonly 
potentially targeted intra-cellular pathways by the miRNAs evaluated. Across all miRNAs, there were 
commonalities across targeted pathways. These include networks of DNA replication, recombination 
and repair; gene expression; cellular organization; intracellular and cell-to-cell signaling; cell growth 
and differentiation; and cell movement. The normal function of these biological processes within 
cells is essential in maintaining normal cellular function; and it is clear that disruption of these 
processes eventually results in the hallmarks of cancer, and carcinogenesis. Dysregulation of 
miRNAs, as demonstrated in HPV-associated tumours in this study, have the ability to disrupt these 
cellular functions through the pathways described, among others, and therefore potentially represent 
a mechanism of carcinogenesis in these tumours. This deserves further study in detail with 
experimental demonstration of gene expression in relation to miRNA expression.  
 
Many genes identified as potential miRNA targets in this study participate in intracellular networks 
known to be disrupted in HPV-related HNSCC, including cell cycle regulation and p53 signaling 
pathways, the PI3KCA-AKT pathway, NOTCH signaling pathway, and -catenin-Wnt pathway [98-
104]; and these pathways were identified in the top canonical pathways affected by several miRNAs 
investigated in this study. Many of these putative targets have also been experimentally validated by 
other authors, as listed in MiRTarBase (Refer to Table 5.2) [83]. However, whether miRNA 
dysregulation alone acts as a driver of carcinogenesis in head and neck cancers; or occurs as a function 
of genomic instability or HPV oncoprotein function with subsequent cell cycle dysfunction, remains 
to be experimentally determined. Regardless of this however, the evident differences in miRNA 
expression and gene expression between HPV-related and unrelated tumours allows for further study 
into the clinical applicability of these differences in the diagnostics, therapeutics and prognostics of 
head and neck cancer.  
 
Table 5.2: A comparison of major genes participating in cellular pathways commonly dysregulated 
in HPV-related HNSCC, comparing results obtained from IPA interrogation (Refer to Chapter Four), 
with experimentally validated target genes for each miRNA (obtained from MiRTarBase [83]). 
Cellular 
pathway 
Target genes (IPA) and corresponding putative target 
miRNAs 
MiRTarBase identified 
experimentally validated miRNAs 
for corresponding target gene 
RB miR-20b miR-20b 
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Cell cycle 
regulation 
 
E2F miR-15, miR-16, miR-20b, miR-30e, 
miR-148b, miR-150, miR-205, miR-
363 
miR-15, miR-16, miR-20b, miR-205  
WEE1 miR-15, miR-16, miR-20b miR-15, miR-16, miR-20b 
Cyclin E miR-15, miR-16, miR-30e, miR-363 miR-15, miR-16 
Cyclin D1 miR-15, miR-16, miR-20b, miR-29a, 
miR-29c, miR-150, miR-155 
miR-15, miR-16, miR-20b, miR-29a, 
miR-155 
CDK4/6 miR-15, miR-16, miR-29a, miR-29c, 
miR-148b, miR-363 
miR-15, miR-16, miR-29a 
NOTCH NOTCH miR-30e, miR-205, miR-150, miR-
16, miR-29c, miR-29a, miR-15,  
miR-15, miR-16, miR-30e, miR-150, 
miR-205 
MAM miR-30e,  miR-30e 
NUMB miR-146a,  miR-146a 
FURIN miR-16, miR-15, miR-20b,  miR-15, miR-16 
PI3KCA-
Akt 
AKT miR-15, miR-16, miR-20b, miR-29c, 
miR-150 
miR-15, miR-16, miR-20b, miR-29c  
PI3K miR-15, miR-16, miR-20b, miR-29a, 
miR-29c, miR-30e, miR-142, miR-
148b, miR-150, miR-363 
 
PTEN miR-20b, miR-29a, miR-29c, miR-
148b, miR-205, miR-363 
miR-20b, miR-29a, miR-29c, miR-
205 
JAK miR-20b, miR-30e miR-20b, miR-30e 
BCL-2 miR-15, miR-16, miR-20b, miR-30e, 
miR-205 
miR-15, miR-16, miR-20b, miR-205  
Integrin  miR-15, miR-16, miR-20b, miR-29a, 
miR-29c, miR-30e, miR-148b, miR-
150, miR-363 
miR-15, miR-16, miR-20b, miR-29a, 
miR-29c,  miR-30e, miR-148b, miR-
150, miR-363 
B-catenin-
Wnt 
Frizzled miR-363, miR-342, miR-30e, miR-
150, miR-148b, miR-146a, miR-16, 
miR-29c,  miR-29a, miR-15, miR-
20b,  
miR-15, miR-16, miR-20b, miR-30e, 
miR-148b,  miR-363 
TGFBR miR-363, miR-342, miR-30e, miR-
155, miR-150, miR-148b, miR-142, 
miR-16, miR-29c, miR-29a, miR-15, 
miR-20b,  
miR-15, miR-16, miR-20b, miR-142  
SOX miR-363, miR-342, miR-30e, miR-
155, miR-150, miR-148b, miR-142, 
miR-16,  miR-29c, miR-29a, miR-15, 
miR-20b,  
miR-15, miR-16, miR-20b, miR-30e, 
miR-148b,  miR-150, miR-363  
Wnt miR-342, miR-155, miR-148b, miR-
16, miR-15, miR-20b,  
miR-15, miR-16, miR-148b, miR-
155 
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Groucho miR-20b, miR-15, miR-16, miR-155, 
miR-150, miR-205,  
miR-15, miR-16  
RAR miR-361, miR-30e, miR-205, miR-
146a, miR-142, miR-16, miR-29c, 
miR-29a, miR-15, miR-20b,  
miR-15, miR-16  
 
 
5.4 Future directions of research  
There are a number of directions in which future research in this area can go. One of the first projects 
to arise from this study would be the validation of the putative target genes put forward in this thesis 
as experimentally validated targets of each respective miRNA. In squamous cell carcinoma cell lines, 
after confirming the expression of the miRNA in question using qRT-PCR, a number of assays can 
be performed to determine whether the gene in question is a valid target. Western blot analysis can 
be used to determine the presence and level of gene expression. Dual luciferase reporter assays can 
be utilised following this to confirm the gene as a miRNA target, by measuring and comparing 
luciferase activity when cells are transfected with anti-miR-x (or double stranded siRNA) and miR-
x. Western blot can further be applied to measure gene expression in cells transfected with anti-miR-
x (knockdown of the miR in question). Cell proliferation and apoptosis assays could also be 
performed to determine any effect of miR-x expression or knockdown on gene expression and 
subsequently on cellular function.  
 
5.4.1 Diagnostics 
Another possible avenue for further research in this area involves the development of a screening 
tool. There is an urgent need for a screening tool to be developed as although HPV associated tumours 
have an improved survival when compared with HPV unrelated tumours, a small number of these 
patients do not [8]. The majority of patients continue to present at a more advanced stage at diagnosis. 
As a consequence, the overall mortality for head and neck cancer remains at approximately 50%, 
despite advances in treatment over the past decade; as well as the ongoing significant morbidity 
associated with treatment [1, 6]. A screening tool which can be widely applied to the general 
population has the potential to dramatically improve both morbidity and mortality rates by enabling 
earlier detection of tumours.  
 
The ability for a set of miRNAs to distinguish normal human tissue from tumour tissue has been well 
demonstrated [52, 105]. MiRNAs are unique as tissue biomarkers as they are secreted by cells as 
exosomes or extracellular vesicles, and remain stable in body fluids [106, 107]. The combination of 
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these discoveries means that miRNAs are well suited as readily available and less invasive (than 
tissue biopsies) biomarkers for disease diagnosis. In several human malignancies, studies have been 
performed to demonstrate the effectiveness of miRNAs as diagnostic biomarkers. For example, in 
cholangiocarcinoma, a panel of miRNAs in bile predicts early stage disease with a sensitivity of 67% 
and a specificity of 96%; and when combined with CA19-9 the sensitivity increased to 96% [108]. 
In lung cancer a miRNA signature has been found to have a similar sensitivity and specificity to CT 
imaging for the detection of primary tumours in at-risk cohorts; while a further set of miRNAs has 
been found to distinguish between early tumours and benign nodules [109-111].  
 
In HNSCC, studies have demonstrated differences between tumour and normal tissue in the head and 
neck [57]; as well as the ability to differentiate HNSCC tumour origin in lymph node metastasis of 
unknown primary [51, 65]. Focus on the search for a screening tool is shifting to saliva as a readily 
accessible body fluid, and although research lacks behind that of other human malignancies, there is 
promise in the search for an accurate screening tool [70, 112]. To determine whether a panel of 
miRNAs can be utilised as a screening tool, the panel identified in tumours would first need to be 
compared with a cohort of normal tissue, such as normal tonsillar tissue. However, this is difficult to 
obtain because of the risks obtained with removing tissue from a normal, control patient. Another 
way to get around this would be to identify a panel of miRNAs in a body fluid such as saliva or 
plasma, with a comparison of expression between patients with HPV associated and non-associated 
tumours, and normal controls. If a difference is observed between the three cohorts, pre-malignant 
lesions can be introduced.  
 
5.4.2 Therapeutics  
The obvious potential application of target gene validation for any given miRNA is the future 
development of novel therapeutic agents. The most appealing property of miRNAs therapeutically is 
their ability to target a number of different mRNAs and intracellular pathways, resulting in efficient 
regulation of particular biological processes. There are two mechanisms currently in practice for 
therapeutic targeting of miRNA expression in cancer. Indirectly, drugs that target miRNA 
transcription or processing can be used to modulate miRNA expression; or oligonucleotides can be 
used to either introduce a lost tumour suppressor miRNA or silence the expression of an oncogenic 
miRNA [113]. There are a number of siRNA-based therapeutics currently in pre-clinical development 
or undergoing clinical trials. For example, a systemically delivered siRNA targeting p53 has 
completed a phase I trial in prevention of delayed graft function in patients undergoing kidney 
transplantation, and is currently in phase II trials (results unpublished, Quark Pharmaceuticals) [113]. 
A systemically delivered siRNA first commenced clinical trials for a solid human cancer, melanoma, 
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in 2008; however, this trial was ceased due to toxicities [114]. Since then, a number of siRNA 
therapeutics have been formulated. In pancreatic adenocarcinoma, a siRNA targeting PKN3 has been 
shown to cause stabilization or regression of disease with no toxicities (Silence Therapeutics) [115]. 
Clinical trials are also underway for siRNAs targeting MYC in hepatocellular carcinoma, solid 
tumours and non-Hodgkin lymphoma (Dicerna Pharmaceuticals) [113]. Although this area has yet to 
develop in head and neck cancer, there has been clear progress in miRNA therapeutics in a number 
of human cancers; and the therapies currently undergoing clinical trials hopefully will also be 
applicable to this specialty in the future.  
 
5.4.3 Prognostication 
This study has identified several miRNAs which are associated with recurrence of primary disease 
and disease-specific survival in HPV-associated head and neck cancer. Several other studies, as 
outlined above, have also reported similar findings although the literature lacks consistency given the 
small number of studies. Regardless, miRNAs have clear promise as prognostic biomarkers in head 
and neck cancer, and this deserves further study. In an era of therapy de-intensification, a miRNA 
profile associated with recurrence, progression of disease or survival can be utilised in clinical 
practice to risk-stratify patients, allowing accurate identification of those patients who still require 
maximal therapy in order to improve their clinical outcomes. This cohort for example, would include 
the approximately 20% of HPV-positive tumours which have a higher recurrence rate and a poorer 
prognosis [1, 18].  
 
Research into the use of miRNAs as prognostic biomarkers is far more advanced in other solid human 
cancers, such as melanoma, breast cancer and lung cancer. For example, Australian studies in Stage 
IV melanoma patients have identified a panel of miRNAs which associate with progression of disease 
and prognosis [78, 79]. This panel is readily identifiable in plasma, and could potentially be applied 
clinically [78]. Similarly, studies in lung cancer are far more advanced, and sets of prognostic 
miRNAs which are identifiable in plasma have been identified and correlated across multiple studies 
[116-118].  Over-expression of miR-21 has been identified as a predictor of poorer prognosis across 
a range of solid and haematological human cancers, including pancreatic and colon adenocarcinoma 
[119, 120], chronic lymphocytic leukaemia [50, 121], lung cancer [122], as well as HNSCC [62, 64].  
 
In order to develop a prognostic biomarker panel from the results of the present study, the first step 
will be to identify both the presence of these miRNAs in the saliva or plasma of patients with a 
recurrence of their tumour, and their absence in normal controls and patients without recurrence. Then 
a feasibility study could be performed, measuring a miRNA panel in the saliva or plasma of HPV-
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associated HNSCC patients, with collections at diagnosis, and at spaced intervals (with clinical 
follow-up) for a period of over two years. The majority of recurrences occur within the first two years, 
and therefore to maximize the number of patients with a recurrence of their disease, the study should 
be continued for at least this period of time.  
 
5.5 Discussion of study 
5.5.1 Strengths of study 
The main strength of the present study is the sample size, being the largest investigating miRNA 
expression in head and neck squamous cell carcinoma to date, as well as the largest study 
investigating miRNA expression in HPV positive and negative tumours. It is also the first study to 
use the Fluidigm PCR system for miRNA validation in the study of head and neck cancers; and the 
first study of this kind in Australia. The methods utilized in these experiments are robust and well 
validated in the literature; and the use of RNU-48 as an endogenous control and performance of all 
assays in quadruplicate for each sample enhanced this. We used the most recent and up to date version 
of miRBase (v.21), enabling identification on microarray of all identified human miRNAs to date. 
Finally, the data collection was robust and the medical questionnaires completed by patients were 
extensive in the number and detail of variables obtained. Medical data was also thoroughly collected 
to ensure that recurrence and mortality data was up to date (2017) at the time of submission. Longer 
follow-up of patients included in the study, of over ten years from initial data collection (2004 – 
2017), ensured that a higher number of events were detected, lending quality to our results.  
 
5.5.2 Limitations of study 
Although large cohort numbers is a strength of this study, we had smaller numbers of HPV positive 
tumours at subsites outside of the oropharynx, which although unfortunate, is a reflection of the 
clinical demographics of HPV associated tumours. However, this does significantly limit the 
interpretation of results at these other subsites. Secondly, no normal human tissue was included for 
comparison with the tumour miRNA expression results. Previous studies have used a variation of 
tissues as controls, including cell lines, adjacent ‘normal’ tissue, and additionally sampled ‘normal’ 
mucosa. The difficulty with using ‘normal’ tissue obtained from directly adjacent to the tumour is 
that there have not been any studies investigating whether the miRNA expression in this ‘normal’ 
appearing tissue is significantly similar to healthy squamous oral mucosa. For this reason, and given 
that the aim of this project was to directly compare the HPV-positive and negative tumours for 
miRNA expression, normal tissue controls were not included in the study design.  
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Finally, the identification of putative target genes for each miRNA was heavily reliant on three online 
target gene prediction algorithms, which are detailed above. Although we used a combination of these 
databases with the aim of improving target prediction accuracy, these are notoriously inaccurate, and 
are not all equally up to date. As a result, any identified potential target genes should be 
experimentally validated before being considered a target for any given miRNA; and the results of 
target gene prediction for each investigated miRNA therefore open up many future avenues for 
experimental target gene validation.  
 
5.6 Conclusions 
In conclusion, this study has identified a number of miRNAs which are differentially expressed in 
HPV-positive tumours, when compared with HPV-negative tumours. Differential miRNA expression 
was also demonstrated with lifestyle factors such as tobacco smoking and alcohol consumption, as 
well as with dysregulation of cell cycle factors including p16INK4a and cyclin D1. MiRNAs were also 
identified to be associated with clinical features including increasing stage at diagnosis, recurrence 
of disease and disease-specific survival. There are a number of directions in which future research 
can progress on the basis of these findings, as described above, although two important avenues 
would be the development of a screening tool to aid earlier diagnosis; and the development of a 
miRNA panel for prognostication, in order to identify those patients who will require intensive 
therapy as opposed to those who would be suitable for treatment de-intensification. HPV-related 
tumours of mucosal head and neck sites are clearly distinct in both clinical behavior and in the 
molecular mechanisms underlying tumour development, and this study has added to our 
understanding of the latter.  
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APPENDIX ONE: Supplementary Tables and Figures  
 
Supplementary Table 3.1: Microarray results for differentially expressed miRNAs between HPV-
positive and negative tumours at a fold change of >2.0 and p value <0.01. This revealed forty-nine 
biologically significant miRNAs which are differentially expressed, nine of which are down-
regulated in HPV-related tumours, and forty of which are up-regulated.  
 
miRNA Fold 
Change 
P value Direction 
of change 
miRNA Fold 
Change 
P value Direction of 
change 
hsa-miR-et-7g-5p 2.16 0.001 Up hsa-miR-205-3p 6.50 7.94E-4 Up 
hsa-miR-15a-5p 5.64 1.26E-4 Up hsa-miR-221-5p 2.81 0.005 Up 
hsa-miR-15b-3p 2.80 0.005 Up hsa-miR-340-5p 3.06 0.006 Up 
hsa-miR-15b-5p 2.67 2.81E-4 Up hsa-miR-342-3p 3.74 9.47E-6 Up 
hsa-miR-16-2-3p 8.73 3.70E-5 Up hsa-miR-342-5p 4.03 0.001 Up 
hsa-miR-16-5p 2.21 2.62E-4 Up hsa-miR-361-3p 7.12 2.96E-4 Up 
hsa-miR-20b-5p 5.17 0.001 Up hsa-miR-363-3p 7.42 1.66E-4 Up 
hsa-miR-26b-5p 2.28 0.005 Up hsa-miR-425-5p 2.86 0.002 Up 
hsa-miR-29a-3p 2.75 3.90E-4 Up hsa-miR-497-5p 2.45 0.008 Up 
hsa-miR-29b-3p 4.43 0.001 Up hsa-miR-664b-3p 3.11 0.006 Up 
hsa-miR-29c-3p 3.85 0.001 Up hsa-miR-1224-5p 3.47 0.006 Down 
hsa-miR-29c-5p 5.18 0.005 Up hsa-miR-1268a 2.33 0.001 Down 
hsa-miR-30e-5p 2.60 3.90E-4 Up hsa-miR-1271-5p 3.27 0.009 Up 
hsa-miR-34a-5p 2.16 0.002 Up hsa-miR-1275 2.09 0.002 Down 
hsa-miR-101-3p 4.35 0.009 Up hsa-miR-3607-3p 2.39 5.72E-5 Up 
hsa-miR-140-5p 2.70 0.004 Up hsa-miR-3653-5p 4.64 0.003 Up 
hsa-miR-142-3p 9.87 3.55E-4 Up hsa-miR-3937 3.85 0.005 Up 
hsa-miR-142-5p 8.77 1.50E-4 Up hsa-miR-4484 3.06 6.44E-4 Down 
hsa-miR-146a-5p 3.06 3.12E-6 Up hsa-miR-6722-3p 2.74 0.003 Down 
hsa-miR-146b-5p 2.03 0.006 Up hsa-miR-6754-5p 6.59 0.002 Down 
hsa-miR-148b-3p 4.56 0.006 Up hsa-miR-6756-5p 3.22 0.006 Down 
hsa-miR-150-5p 6.55 2.10E-5 Up hsa-miR-6763-5p 6.42 0.004 Down 
hsa-miR-155-5p 4.13 5.83E-6 Up hsa-miR-6771-5p 3.81 0.006 Down 
hsa-miR-192-5p 4.27 0.003 Up hsa-miR-7848-3p 3.51 0.005 Up 
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Supplementary Table 3.2: Microarray results for differentially expressed miRNAs in p16INK4a 
positive compared with p16INK4a negative tumours in the oropharynx, with a fold change of >2.0 and 
p value of <0.05. This revealed forty-five biologically significant miRNAs which are differentially 
expressed; three of which are down-regulated in p16INK4a positive tumours, and forty-two of which 
are up-regulated. 
 
miRNA 
Fold 
change p value 
Direction 
of change miRNA 
Fold 
change p value 
Direction of 
change 
hsa-let-7g-5p 2.11 6.93E-03 Up hsa-miR-150-5p 7.23 5.06E-05 Up 
hsa-miR-10a-5p 3.43 3.21E-02 Up hsa-miR-155-5p 4.14 2.38E-05 Up 
hsa-miR-15a-5p 5.67 1.93E-03 Up hsa-miR-192-5p 3.52 3.84E-02 Up 
hsa-miR-15b-3p 2.81 2.14E-02 Up hsa-miR-195-5p 2.93 3.63E-02 Up 
hsa-miR-15b-5p 2.40 9.58E-03 Up hsa-miR-205-3p 5.23 6.04E-03 Up 
hsa-miR-16-2-3p 7.44 4.12E-04 Up hsa-miR-221-5p 2.82 1.37E-02 Up 
hsa-miR-16-5p 2.10 4.33E-03 Up hsa-miR-331-3p 2.92 4.29E-02 Up 
hsa-miR-19b-3p 3.84 4.81E-02 Up hsa-miR-340-5p 2.63 2.57E-02 Up 
hsa-miR-20b-5p 3.97 2.67E-02 Up hsa-miR-342-3p 3.33 2.41E-04 Up 
hsa-miR-26b-5p 2.22 4.81E-02 Up hsa-miR-342-5p 4.04 2.91E-03 Up 
hsa-miR-29a-3p 2.74 3.42E-03 Up hsa-miR-361-3p 6.94 4.40E-04 Up 
hsa-miR-29b-3p 4.46 9.37E-03 Up hsa-miR-363-3p 6.13 9.65E-04 Up 
hsa-miR-29c-3p 4.30 2.27E-03 Up hsa-miR-374c-5p 3.81 3.87E-02 Up 
hsa-miR-29c-5p 4.73 1.85E-02 Up hsa-miR-425-5p 2.13 1.65E-02 Up 
hsa-miR-30e-3p 3.67 2.50E-02 Up hsa-miR-664b-3p 3.27 3.51E-02 Up 
hsa-miR-30e-5p 2.54 5.26E-03 Up hsa-miR-664b-5p 4.97 2.65E-02 Up 
hsa-miR-34a-5p 2.22 1.08E-02 Up hsa-miR-3607-3p 2.40 3.23E-04 Up 
hsa-miR-125b-2-3p 3.29 4.83E-02 Up hsa-miR-3653-5p 5.18 1.86E-03 Up 
hsa-miR-125b-5p 2.29 4.98E-02 Up hsa-miR-5001-5p 2.24 3.98E-02 Down 
hsa-miR-140-5p 2.34 4.72E-02 Up hsa-miR-5006-5p 3.37 2.19E-02 Down 
hsa-miR-142-3p 10.48 1.24E-03 Up hsa-miR-6516-3p 3.09 4.49E-02 Up 
hsa-miR-142-5p 7.14 2.40E-03 Up hsa-miR-7848-3p 2.27 4.05E-02 Down 
hsa-miR-146a-5p 2.88 8.31E-05 Up     
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Supplementary Table 3.3: Microarray results for differentially expressed miRNAs in p16INK4a 
positive compared with p16INK4a negative tumours in the oropharynx, with a fold change of >2.0 and 
p value of <0.001. This revealed eighteen biologically significant miRNAs which are differentially 
expressed; one of which was down-regulated in p16INK4a positive tumours, and seventeen of which 
are up-regulated.  
 
miRNA Fold Change p value Direction of change 
hsa-miR-15a-5p 5.66 0.005 Up 
hsa-miR-16-2-3p 7.43 0.002 Up 
hsa-miR-16-5p 2.10 0.009 Up 
hsa-miR-29a-3p 2.73 0.007 Up 
hsa-miR-29c-3p 4.30 0.005 Up 
hsa-miR-30e-5p 2.53 0.009 Up 
hsa-miR-142-3p 10.48 0.004 Up 
hsa-miR-142-5p 7.14 0.005 Up 
hsa-miR-146a-5p 2.87 9.42E-4 Up 
hsa-miR-150-5p 7.22 9.09E-4 Up 
hsa-miR-155-5p 4.14 8.82E-4 Up 
hsa-miR-342-3p 3.32 0.002 Up 
hsa-miR-342-5p 4.03 0.009 Up 
hsa-miR-361-3p 6.93 0.003 Up 
hsa-miR-363-3p 6.13 0.005 Up 
hsa-miR-3607-3p 2.40 0.002 Up 
hsa-miR-3653-5p 5.18 0.005 Up 
hsa-miR-4484 2.72 0.009 Down 
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Supplementary Table 3.4: Microarray results for differentially expressed miRNAs in non-
smokers, compared with smokers, in the oropharynx, with a fold change of >2.0 and p value of 
<0.01. This revealed fifteen biologically significant miRNAs which are differentially expressed; all 
of which are up-regulated in non-smokers. 
 
miRNA Fold Change p value Direction of change 
hsa-miR-19a-3p 2.62 9.44E-4 Up 
hsa-miR-34c-5p 2.34 8.51E-4 Up 
hsa-miR-196b-3p 2.36 0.001 Up 
hsa-miR-301a-3p 2.66 0.001 Up 
hsa-miR-584-5p 2.41 6.05E-4 Up 
hsa-miR-1245a 2.43 7.00E-4 Up 
hsa-miR-1914-3p 4.81 0.002 Up 
hsa-miR-3679-5p 2.40 0.003 Up 
hsa-miR-4289 2.78 0.003 Up 
hsa-miR-4327 2.32 0.004 Up 
hsa-miR-5011-3p 2.36 0.001 Up 
hsa-miR-6068 9.59 0.005 Up 
hsa-miR-6735-3p 2.35 0.001 Up 
hsa-miR-7155-5p 2.48 0.001 Up 
hsa-miR-7162-3p 2.38 0.001 Up 
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Supplementary Table 3.5: Microarray results for differentially expressed miRNAs in oropharyngeal 
tumours who did not have a recurrence of their primary tumour, compared with those who did; with 
a fold change of >2.0 and p value of <0.05. This revealed eleven biologically significant miRNAs 
which are differentially expressed; one of which was down-regulated in patients without a recurrence, 
and ten of which were up-regulated.  
 
miRNA Fold Change p value Direction of change 
hsa-miR-16-2-3p 3.30 0.044 Up 
hsa-miR-142-3p 4.37 0.041 Up 
hsa-miR-146a-5p 2.14 0.003 Up 
hsa-miR-150-5p 4.14 0.016 Up 
hsa-miR-155-5p 3.06 0.007 Up 
hsa-miR-205-3p 3.57 0.043 Up 
hsa-miR-342-3p 2.58 0.011 Up 
hsa-miR-483-5p 4.36 0.011 Down 
hsa-miR-1301-5p 2.91 0.030 Up 
hsa-miR-3607-3p 2.18 0.013 Up 
hsa-miR-3607-5p 2.31 0.042 Up 
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Supplementary Figure 3.1: Heat map corresponding to Supplementary Table 3.1, visually 
demonstrating the difference in miRNA expression between HPV positive (blue) and HPV negative 
(red) oropharyngeal tumours, with a fold change of >2.0 and p <0.01. miRNAs which are up-
regulated in HPV positive tumours are designated red and those which are down-regulated are 
designated green. 
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Supplementary Figure 3.2: Heat map corresponding to Supplementary Table 3.2, visually 
demonstrating the difference in miRNA expression between p16INK4a positive (red) and p16INK4a 
negative (blue) oropharyngeal tumours, with a fold change of >2.0 and p <0.05. miRNAs which are 
up-regulated in p16INK4a tumours are designated green and those which are down-regulated are 
designated red.  
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